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1. INTRODUCTION 
1.1 HISTORY 
The discovery of vitamin К was the result of serendipity. In 1929 Dam observed that 
chicks fed on a lipid-free diet developed a haemorrhagic condition (1). A few years 
later he proposed that the active compound was a new fat-soluble anti-haemorrhagic 
vitamin that he called vitamin К (koagulation). At that time the belief was that the 
bleeding tendency of animals fed on vitamin K-deficient diets was solely caused by a 
lack of prothrombin. A few decades later factors VII, IX and X were discovered. In 
the meanwhile vitamin K; was isolated and characterized. The compounds isolated 
from putrefied fishmeal differed from vitamin K; in structure and properties, and were 
called vitamins K2. For their discoveries of vitamin Ky and K ,^ Dam and Doisy 
received the Nobel prize in physiology and medicine (1). The role of vitamin К in the 
synthesis of clotting factors was elucidated in the 1970s with the demonstration that 
prothrombin contains a number of residues of γ-carboxyglutamic acid, a hitherto 
unidentified amino acid, (2). These residues are added to the hepatic precursor proteins 
in a vitamin K-dependent step. The molecular role of vitamin К is clear; it acts as a 
cofactor for an enzyme that carboxylates peptide-bound glutamic acid residues to γ-
carftoryglutamic acid residues, see Fig. 1.1. 
Prothrombin 
Precursor Prothrombin 
1 
CH2 
Carboxylase 
Vitamin К • > 
COOH COOH 
Glutamyl 
residue 
(Glu) 
y-Carboxy-
Glutamyl 
residue 
(Gla) 
Fig. 1.1 Vitamin K-dependent carboxylation. 
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As early as 1894, Townsend reported that haemorrhages with a self-limiting and 
definite character occurred in newborns. He was the first to classify them all together 
under the name 'Haemorrhagic Disease of the Newborn (HDN)' (3). An infectious 
aetiology was assumed. After the discovery of vitamin К it was soon established that 
HDN was caused by a deficiency of vitamin К and that administration of vitamin К was 
effective in therapy as well as prevention of HDN (4). In 1961 the Committee on 
Nutrition of the American Academy of Pediatrics recommended to administer vitamin 
К prophylaxis to all newborn infants (5). Since then, many countries have adopted this 
recommendation, although controversies concerning the optimal dose, route and 
frequency of administration still exist. 
1.2 STRUCTURE AND NOMENCLATURE OF VITAMIN К 
The nomenclature of compounds possessing vitamin К activity has been modified a 
number of times. The term vitamin К is used as a generic descriptor of 2-methyl-l,4-
naphtoquinone and all derivatives of this compound that exhibit an antihaemorrhagic 
activity in animals fed on a vitamin K-deficient diet. The naphtoquinone nucleus and 
2-methyl group are essential. Without them anti-haemorrhagic activity is precluded. The 
nomenclature of some compounds is presented in Table 1.1; their structure is depicted 
in Fig. 1.2. 
Menadione Phylloquinone 
Menaquinone-7 
Fig. 1.2 Structure of vitamin К compounds 
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Table 1.1 Nomenclature of vitamin К. All compounds have a 2-methyl-l,4-naphtoquinone 
nucleus but differ in their side chain. 
Side chain IUP A C Abbreviation 
(I) 
(") 
(HI) 
e.g. 
-
3-phytyl 
3-(ргепу1)ль 
3-(prenyl)7 
menadione 
phylloquinone 
menaquinone-n* 
menaquinone-7 
K5 
Щ
 t / ^ 1(20) 
MK-n* / K2(n)c 
MK-7 IVL2(35) 
a
, according to the International Union of Pure and Applied Chemistry (6). 
b
, η represents the number of prenyl units in the side chain. 
c
, η represents the number of carbon atoms in the side chain. 
I. Vitamin Kj or menadione is not a natural vitamin K. It is more water-soluble than 
the other vitamin К compounds. In vitro menadione is not biologically active; in vivo 
it is metabolized to MK-4 (7). Because of the lack of a side chain, menadione can 
react with sulfhydryl groups of the erythrocyte membrane and can thus cause 
haemolysis and severe hyperbilirubinaemia (8). 
II. Vitamin Ky or phylloquinone is also called Phytomenadione. Natural vitamin K^ is 
the trans isomer at the 2*3' position of the phytyl side chain. Cis isomers are inactive. 
Konakion , which is the vitamin Ky solution used for vitamin К prophylaxis in this 
study, contains both trans en cu vitamin Щ in a ratio of 88:12 (9). 
III. Vitamins K2 or menaquinones are a series of vitamin К compounds with 
unsaturated side chains found in animal tissues and in bacteria. Menaquinones with up 
to 13 prenyl-groups have been identified, as well as several partially saturated kinds 
(10). The length of the 3-isoprenoid side chain and its saturation account for 
differences in biological activity. In vitro studies have demonstrated that menaquinones 
2 to 6 show cofactor activity which is more or less comparable to that of vitamin Kj. 
Menaquinones with longer side chains are less active (11). 
1J PHYSICAL AND CHEMICAL PROPERTIES OF VITAMIN К 
Vitamin Ky or phylloquinone is a yellow coloured oil at room temperature, while the 
menaquinones have melting points ranging from 35 to 60 "С. Phylloquinone has a 
molecular weight of 450.7 Da, MK-4 of 444 Da and MK-13 of 1056 Da. In normal light 
the vitamins are subject to ultraviolet decomposition, therefore handling should be 
performed in subdued lighting. Vitamin К is sensitive to alkali, but is relatively stable 
to heating and freezing. The oxidized forms of the К vitamins exhibit an ultraviolet 
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spectrum that is characteristic of the naphtoquinone nucleus. The vitamins have no 
native fluorescence, but the reduced hydroquinones are highly fluorescent. Vitamin Kj 
is hydrophobic and insoluble in aqueous solutions. In serum it is transported by 
lipoproteins (12) and in milk in the lipid core of the milk fat globules (13). 
1.4 SOURCES OF VITAMIN К AND RECOMMENDED DIETARY INTAKE 
1.4.1 Adults 
Sources in adults 
Reported vitamin K¡ contents of various commonly consumed foods vary widely. To 
what extent this variation is due to an actual variation in vitamin content of the 
product, or differences in bioavailability, or error in laboratory methods cannot be de-
termined from the existing data. In general, green and/or leafy vegetables are the best 
source of vitamin K¿. For example, fruits and potatoes contain less than 10 /ig/lOOg, 
while spinach and broccoli contain more than 100 μg/100 g (7). The vitamin seems 
stable in food processing and meal preparation. 
To what extent vitamin / ^ is important in adult vitamin К supply has not been 
established yet. Menaquinones account for some 90% of total hepatic stores of vitamin 
К (14, 15), but it is unknown whether these are the result of bacterial synthesis in the 
gut or due to food contamination (16). 
RDI for adults 
Recommended dietary intake (RDI) for adults is calculated to be about 1 /ig/kg/day 
or 80 ¿ig for men and 65 /ig for women (17). Many other estimates, however, are 
reported; e.g. 0.5 ^g/kg/day, 45 /xg for men and 35 μg for women (18). A normal mixed 
diet consumed daily by a healthy adult has been estimated to contain an average of 
200-400 /tg of vitamin K^  (19). Therefore, in normal healthy adults vitamin К deficiency 
is rare. Nevertheless, vitamin К deficiency has been reported in hospitalized patients 
on antibiotic therapy (20, 21, 22), and in postmenopausal women with osteoporosis 
(23, 24). 
1.4.2 Infants 
Sources in breast-fed infants 
In neonates and young infants vitamin Kj supply is provided by milk-intake solely. 
Human milk is relatively low in vitamin Щ: the mean concentration is about 2 μg/l, 
while the mean for cows' milk is about 4.9 /ig/1 (25). Vitamin Ky concentrations 
reported in human milk vary, due to differences in: 
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1. - Sampling procedure. The composition of milk varies with the method of 
expression (hand ν electric). Contamination of menaquinones from skin bacteria 
must be avoided (26). 
2. - Moment of sampling; 
a. day of lactation. Colostrum (0 - 7 days) seems to have a higher concentration 
of vitamin K; than mature milk (25, 27). However, since volumes of colostrum 
are limited, the total dose of vitamin K^ ingested in the first week of life is 
small (13). Thereafter, vitamin Kj concentration in human milk remains 
constant (13, 19), and since daily volumes of milk also remain constant after 
the first few weeks of lactation, vitamin K^ intake per kg body weight decreases 
during growth (19). 
b. moment of the day. Many lipids show diurnal variation (26). 
с moment during feeding. Hind milk is higher in vitamin K/ than fore milk 
(27). 
3. - Determination technique. Differences in extraction and detection method 
account for differences in sensitivity and specificity. 
Some reported concentrations are represented in Table 1.2. The concentration cannot 
be predicted by dietary intake of vegetables or fat by the mother (13, 19). Oral 
administration of extra vitamin K^  (100 ^g-20 mg) to the mother increases the vitamin 
К ; content of her breast milk significantly (13,19,25,27,28,29). 
Table 1.2 Vitamin Kj concentratrion in human milk (¡igll). 
Author 
Haroon 1982 
Motohara 1984 
von Kries 1987 
Canfield 1991 
Greer 1991 
(Ref) 
(25) 
(30) 
(27) 
(13) 
(19) 
mature milk 
2.1 
3.8 ± 0.9 
1.2 
2.9 ± 2.4 
0.9 ± 0.5 
{rif 
(20) 
(337) 
(9) 
(60) 
(23) 
colostrum 
2.3 
--
1.8 
3.4 ± 2.7 
0.6 ± 0.4 
{nf 
(9) 
(9) 
(15) 
(10) 
a
, number of samples studied 
The amount of vitamin fy in human milk is of no importance. MK-4 to 7 were 
detected in very low concentrations (31), although this could not be confirmed when 
sample contamination by skin bacteria was ruled out (26). 
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Sources in formula-fed infants 
The minimum vitamin K^ concentration for adapted infant formula is 4 /ig/100 kcal, 
corresponding to 26 /ig/1 (32). Although an upper limit cannot be indicated with 
certainty, there is no reason to exceed 20 /ig/100 kcal (100 μξ/\) (33). According to 
manufacturers' statements, Dutch formulas (Nutrilon^, Frisolac^) contain about 7.5-10 
/ig/100 kcal (50-65 μg/l) vitamin K;. In other words, the milk consumed by the Dutch 
breast-fed infants studied in this thesis is about 25 fold lower in vitamin Kj content 
than the milk consumed by Dutch bottle-fed infants. 
In neonates and young infants vitamin Ä^ ·8 0f limited importance. It takes some time 
before gut colonization by vitamin K2 - producing bacteria is established. Correspond-
ingly, menaquinones are not detectable in human liver until the age of 14 days (34). 
Intestinal flora of breast-fed infants is thought to be different from formula-fed infants, 
resulting in less production of vitamin K2 (35). However, Benno et al. (36) noted that 
the numbers of Bacteroides fragilis and Escherichia coli, who are responsible for most 
of the vitamin K2 production, were higher in the faeces of infants with vitamin К 
deficiency compared to faeces of healthy breast-fed infants. Therefore, vitamin К 
deficiency seems to occur regardless of the presence of menaquinone-producing bacteria 
in the gut. 
RDI for infants 
Determining vitamin К requirements for infants is difficult. The American National 
Research Council (17) recommends that infants up to 6 months of age receive 5 /xg/day 
vitamin K, infants 6 to 12 months of age 10 ^g/day, and older children 1 ^g/kg/day. 
Since human milk provides approximately 2 pg/l vitamin K;, breast-fed infants may 
ingest only 1 Mg/day, which amounts only to a mere 20% of the RDI. In a longitudi­
nal study, Greer et al (19) measured a vitamin Kj intake in breast-fed infants of 
approximately 0.1 ¿ig/kg/day during the first 6 months of life. Since vitamin K2 supply 
is minimal, the needs of the breast-fed human infant are scarcely met. Conversely, 
bottle-fed infants are nourished with more than 25 ¿ig/day vitamin K ,^ which is a rather 
generous intake related to the RDI of 5 μ%. Greer et al (19) calculated an intake of 
8 ^g/kg/day in formula-fed infants. Vitamin K^ intake by formula-fed infants was 
approximately 100 times higher than by breast-fed infants. 
1.5 PHARMACOKINETICS 
1.5.1 Absorption 
Vitamin К is absorbed by incorporation in mixed micelles from the intestine into the 
lymphatic system. Bile and pancreatic juice are required. With the addition of 
phosphatidylcholine the amount of solubilized vitamin К increases dramatically (37). 
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Thus, exogenous phospholipid may enhance assimilation of vitamin K .^ This may be 
important to improve preparations for oral vitamin К prophylaxis. 
Vitamin Kj is absorbed by an energy-dependent, saturable process from the proximal 
portion of the small intestine (38). Its resorption is not influenced by the presence of 
vitamin K2 or K3 molecules (38). Intestinal absorption of vitamin K2 displays no 
saturation kinetics. It is absorbed by a passive non-carrier mediated process (38). 
However, whether or not menaquinones synthesized by colonic bacterial flora are ab­
sorbed remains controversial. Some authors conclude that vitamin К deficiency is rare 
in adults because of resorption of vitamin K^ (38), while others suggest that the 
concentration of bile salts in the lower intestinal tract is not sufficient to allow 
physiologically significant absorption of menaquinones (39). Ichihashi et al. (40) 
reported that colonic absorption of radioactive MK-4 and 9 was very limited in rats. 
Absorption in adults 
Shearer et al. (39) and Blomstrand et al. (41) studied absorption of radioactive vitamin 
Kj in normal adults and in patients with impaired fat absorption. Both studies indicated 
that absorption varies widely interindividually. Maximum absorption was calculated to 
be 80%. 
Hagstrom et al. (42) reported that plasma concentrations of vitamin Kj reach a peak 
in 8 hours after an oral dose and in 10 to 30 hours after an intramuscular injection. 
Absorption in infants 
Few studies on the intestinal absorption of vitamin К in the newborn have been 
reported. Lipids are the sole vehicle for fat-soluble vitamins. Infants absorb lipids 
inefficiently, with the preterm infant normally absorbing as little as 60 to 75% of intake. 
The full-term infant may absorb 85 to 90% of intake, but adult values (95%) are not 
achieved until about 4 to 6 months of age (43). Breast-fed infants have the advantage 
of human milk lipase, a nonspecific lipase which may support digestion of lipovitamins 
(44). 
McNinch et al. (45) measured plasma concentrations of vitamin Щ after oral doses of 
1 mg phylloquinone, given either at birth or with the first feed. The absorption curve 
suggested that the peak plasma concentration was attained after 4 hours (median 73 
ng/ml). Thereafter, levels gradually declined. Twenty-four hours after ingestion median 
plasma concentrations had fallen to values of about 30 ng/ml. There was no difference 
between the group who had received the vitamin directly after birth and the group who 
had ingested the vitamin with their first feed. As was the case in adults, absorption 
varied widely interindividually (45). In low-birth-weight infants an intestinal absorption 
rate of 30% has been reported (46). 
After an intramuscular injection of 1 mg vitamin K; plasma concentrations were much 
higher (45). The peak median concentration was 1781 ng/ml at 12 hours. Twenty-four 
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hours after administration concentrations were still about 444 ng/ml. The higher 
concentrations after parenteral administration indicate an inefficient intestinal 
absorption of pharmacological doses. 
In Japan, in contrast to most other countries, an oral syrup of menaquinone-4 is used 
for oral vitamin К prophylaxis instead of phylloquinone. Shinzawa et al. (47) reported 
that, similar to vitamin K ,^ plasma concentrations of MK-4 varied widely after an oral 
dose of 4 mg MK-4. When plasma MK-4 concentrations were corrected for infant's 
weight, a significant negative correlation (r=-0.32, p<0.01) was found between the 
absorption index and plasma concentration of PIVKA-II, which is a biochemical sign 
of vitamin К deficiency (see chapter 2). These results suggest that individual differences 
in vitamin К absorption might contribute to vitamin К deficiency. Subclinical 
malabsorption may be a causative factor in late onset HDN, as confirmed by the 
reports of von Kries et al. (48) and Matsuda et al. (49). In the latter study, reduced 
plasma concentrations of 25-hydroxy-vitamin D and elevated bile acids were found in 
vitamin K-deficient breast-fed infants. This supports the concept of an impaired intest­
inal absorption of vitamin К caused by subclinical cholestasis as a predisposing factor 
for clinical vitamin К deficiency. 
1.5.2 Transport 
Plasma transport 
Vitamin Kj is transported by chylomicrons in the lymphatic system (41) and by 
lipoproteins in plasma (12). In adults, clearance of an injected dose of radioactive 
phylloquinone from plasma shows a two-exponential decline, with a first half-life of 20-
30 min and a second half-life of 120-165 min (50, 51). The disappearance curve in 
newborns seems to be similar to that observed in adults (52). The volume of 
distribution (34 ml/kg) suggests that during the first decline vitamin K; is mainly 
distributed in plasma. During the second decline the mean volume of distribution (345 
ml/kg) is similar to the extracellular volume (52). The plasma clearance was calculated 
to be 78 ml/kg in the first hour and 96 ml/kg during the next 5 hours. 
Transplacental transport 
Placental transport of vitamin K; requires a large maternal-fetal concentration gradient 
(53). A median maternal-cord ratio of 30:1 has been reported, being the highest ratio 
recorded for any fat-soluble vitamin (54). There is no correlation between paired 
maternal and neonatal plasma concentrations. Consequently, pharmacological doses of 
vitamin K; have to be administered to the mother to increase the fetal plasma 
concentration slightly. In addition, there is a lag before vitamin K; crosses the placenta; 
administration of a single oral dose of vitamin Ky to pregnant rats resulted in peak 
maternal plasma concentrations after 2 hours and peak fetal concentrations after 8 
hours (53). This is in accordance with the clinical finding that administration of vitamin 
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Kj to the pregnant mother must be performed more than 4 hours before delivery to 
be beneficial in the prevention of symptoms of vitamin К deficiency in the neonate (55, 
56). 
Similar to vitamin Kj, there seems to be a placental barrier for vitamin K2. While 
vitamin Kj is barely detectable in cord blood, long chain menaquinones are undetect­
able. Only MK-4 can be detected in umbilical cord plasma (31). Administration of 
pharmacological amounts of MK-4 to pregnant women resulted in increased neonatal 
MK-4 plasma concentrations, hence MK-4 can also be applied for prenatal vitamin К 
prophylaxis (28). 
1.53 Storage 
Phylloquinone storage 
Although phylloquinone is rapidly concentrated in the liver, it disappears quickly from 
this organ again. In rat liver peak concentrations lagged behind serum values by 1.5-
3 hours, but then rapidly declined with a half-life of about 10 hours (57). Whole-body 
radiography has demonstrated that vitamin K^ is concentrated by organs other than the 
liver: adrenal glands, lungs, bone marrow, kidneys and lymph nodes have this capacity 
too (58). Whether this distribution is related to a physiological function of the vitamin 
is not elucidated yet. 
Hepatic stores of phylloquinone in neonates appear to be small. Vitamin K; was 
detected in livers of human fetuses as early as 10 weeks, at concentrations of 1-2 ng/g 
liver (fresh weight). Similar concentrations were measured in preterm (median 1.4 ng/g) 
and term (1.0 ng/g) neonates (14). These hepatic concentrations are significantly less 
compared to adult levels, which are reported to be 5.5 ng/g (14) or 12.7 ng/g (15). 
Thus, the ratio of adult versus neonatal hepatic levels is 5:1 or higher. From the liver 
weights, total liver stores of approximately 0.1 ßg for term neonates, 8 ^g (14) and 18 
/jg (15) for adults were calculated, respectively. 
In a postmortem study, it was demonstrated that vitamin К prophylaxis by intra­
muscular injection raises liver stores dramatically (14). After injection of 0.5-1 mg 
vitamin K;, values for hepatic stores increased from 0.1 ^g to 20 ^g in 10 hours. After 
1 to 4 days stores were in the range of 50-200 pg. During these 4 days the proportion 
of the injected dose in the liver ranged from 1 to 52% (median 14%). Two infants who 
lived for 13 and 28 days, had hepatic stores of 24 and 15 /tg, respectively (14). Thus, 
it seems that hepatic stores remain elevated for at least 2 weeks. Whether this is 
similar after an oral application is unknown. 
Menaquinone stores 
Besides vitamin K ,^ different forms of vitamin K2 (MK-4 to MK-13) can be detected 
in adult liver (29). Menaquinones even accounted for some 90% of total hepatic stores 
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of vitamin К on a molar basis (14, 15). In the fetus and neonate menaquinones were 
not detectable until the age of 14 days. Thereafter a gradual build-up was noticed (14, 
29). 
1.5.4 Metabolism and excretion 
Shearer et aL (51) studied metabolism of radioactive phylloquinone in adults. About 
20% of an intravenously injected dose was excreted in the urine and 30-40% was 
excreted in the faeces via the bile. Comparable results were achieved after oral 
administration (12). The vitamin is excreted as more polar metabolites. Phylloquinone 
is metabolized to various oxygenated derivatives, mostly by shortening the side chain 
to 5 or 7 carbon atoms, yielding carboxylic acids which are conjugated with glucuronic 
acid. Only a few of the oxidation products have been identified (39). It is unknown 
whether neonatal vitamin К metabolism differs from adult metabolism. 
1.6 BIOCHEMICAL FUNCTION 
1.6.1 Vitamin K-dependent coagulation proteins 
Hemker et al. (59) were the first to state that a precursor-protein of prothrombin is 
synthesized in the liver cells, which is converted to prothrombin in a vitamin K-
dependent step. When this conversion is inhibited, these precursor-proteins are shed 
in the blood and become detectable. They are called proteins induced by vitamin K's 
absence (PIVKA). The rapid appearance of normal prothrombin in the circulation 
when vitamin К is administered to severly hypoprothrombinaemic vitamin K-deficient 
patients, proves that a significant pool of precursor-protein is present in the liver cells 
and that these proteins can be converted to prothrombin following vitamin К 
administration (60). This response is insensitive to the protein synthesis inhibitor 
cycloheximide (61). 
In 1974 the nature of the vitamin K-dependent modification was elucidated; the 
glutamic acid (Glu) residues of the precursor proteins are modifed to γ-carboxyglutamic 
acid (Gla; 3-amino-l,l,3-propanetricarboxylic acid) residues (Fig. 1.1) (2). All 10 Glu 
residues in the first 33 residues at the aminoterminal end of prothrombin are modified 
in this fashion, while in the remainder of the molecule the Glu residues are not 
carboxylated (61). The Gla residues confer metal binding properties on the vitamin K-
dependent proteins. This allows them to undergo a conformational change in the 
presence of calcium ions, leading to the expression of membrane binding properties. 
In the presence of membrane-bound cofactors, the proteins assemble on membrane 
surfaces and act on membrane-bound substrates. Thus, the Gla rich domain of the 
vitamin K-dependent proteins allows for reversible calcium-dependent protein complex 
formation on cell surfaces (62). Proteins which are uncompletely carboxylated, i.e. the 
PIVKA's, are functionally defective. 
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All vitamin K-dependent coagulation proteins are synthesized in a precursor form that 
consists in a signal sequence, a propeptide and the mature protein (62). A schematic 
presentation of structural domains is shown in Fig. 1.3. The signal peptide serves to 
translocate the polypeptide to the rough endoplasmic reticulum for further post-
translational modification, including signal peptide cleavage, propeptide cleavage, di­
sulfide bond formation, glycosylation and γ-glutamylcarboxylation (61, 62). The 
propeptide designates specific precursor polypeptides for vitamin K-dependent 
carboxylation; in particular, the carboxylation recognition site on the propeptide binds 
tightly to the carboxylase-enzyme (62), see Fig. 1.4. For more information on function 
and structure of other regions the reader is referred to the literature (62,63,64,65,66). 
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Fig. 1.3 Structural domains in the human vitamin K-dependent coagulation factors. SP, 
signal peptide; PP, propeptide; Gla, y-carboxyglutamic acid-rich region; AS, aromatic amino 
acid stack; K, kringle domain; ACT, activation region; CT, catalytic triad; EGF, domain 
homologous to the epidermal growth factor precursor; T, thrombin-sensitive region; SHBG, 
domain similar to the sex homone binding globulin. Modified after Hessing (63). 
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Fig. 1.4 Posttranslational carboxylation of vitamin K-dependent proteins during protein 
synthesis. The signal recognition particle binds to the signal peptide, leading to the 
formation of a ribosome-particle-messenger RNA complex on the endoplasmic reticulum. 
The signal peptide is translocated to the luminal aspect of the rough endoplasmic reticulum. 
After signal peptide cleavage, the propeptide is expressed on the nascent polypeptide chain. 
The propeptide, containing the y-carboxylation recognition site, binds to the vitamin K-
dependent carboxylase associated within the endoplasmic reticulum. Specific glutamic acids 
are converted to y-carboxyglutamic acids, then the protein is transported to the Golgi 
apparatus where the propeptide is cleaved. The fully processed protein is secreted into the 
circulation. (From Furie & Furie (62), with permission). 
Table 1.3 Vitamin K-dependent plasma proteins in adults. 
Factor 
Plasma cone (mg/l) 
Mol. mass (kDa) 
Number of Gla residues 
Half-life (h) 
II 
90 
72 
10 
78 
VII 
0.5 
50 
10 
4 
IX 
4 
57 
12 
22 
X 
6 
59 
11 
40 
С 
4 
62 
9 
7 
S 
30 
71 
11 
? 
Ζ 
1 
55 
13 
? 
Data derived in part from (63, 66). 
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Some properties of the vitamin K-dependent plasma proteins are given in Table 1.3. 
These proteins have a crucial role in both the intrinsic and extrinsic pathway of 
coagulation, which is a cascade system of reactions, initiated upon exposure of blood 
to tissue factor or negatively charged surfaces, leading to the formation of thrombin 
and fibrin, Fig. 1.5. Protein S serves as a cofactor for activated protein С in the 
inactivation of coagulation factors Va and Villa. The function of protein Ζ is still 
unknown. 
EXTRINSIC INTRINSIC 
VII • Vila 
CA 
Phospholipid 
Tissue Factor 
IX 
XIa 
CAJ 
J 
Phospholipid 
CA 
-
I X a
 Villa». 
-VIII 
Xa 
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CA V a » V + 
Prothronbin Thrombin 
Protein S 
Protein Ca 
Protein С 
.ThrombomcduliE 
XIII 
Fibrinogen. _». Fibrin moDomer 
l 
Unstable Polymer 
CA 
Xllla 
Cross Linked Fibrin 
Fig. 1.5 The coagulation cascade. CA, calcium ions. Activated vitamin К 
dependent proteins (eg. Vila, Xa) form complexes, as shown by boxes. 
— activation, .... inhibition. 
Vitamin К deficiency results in incomplete carboxylation of the coagulation proteins 
that no longer form complexes with calcium and phospholipids. A deficiency of 
functional factor II, VII, IX and X is most apparent, resulting in a generalized bleeding 
tendency. 
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1.6.2 Other vitamin K-dependent proteins 
Vitamin K-dependent carboxylase belongs to the standard machinery of almost all 
types of eukaiyotic cells (67). Therefore, it was to be expected that a wide variety of 
Gla-containing proteins would be discovered. Nevertheless, the number of well 
characterized Gla-proteins (G-P) has remained low until now. They include the plasma-
Gla-proteins mentioned previously, and Gla-proteins found in bone and dentine 
(osteocalcin or bone-G-P, and matrix-G-P), in atherosclerotic plaques (atherocalcin or 
plaque-G-P), in urine and renal stones (nefrocalcin or urinary-G-P), in sperm, and in 
snake and snail venom (16, 64). 
All Gla-proteins seem to be involved in calcium mediated processes. The importance 
of these proteins to the fetus is demonstrated by the so-called warfarin embryopathy, 
which occurs when a fetus is exposed to vitamin К antagonists during the first trimester 
of pregnancy. The defects are characterized by excessive calcification of the epiphyses 
and irregular growth of facial and long bones (68). Identical clinical features are 
observed in infants with congenital deficiency of vitamin К epoxide reductase (69). It 
is hypothesized that the bone defects are due to abnormalities in carboxylation of 
osteocalcin. 
1.63 Carboxylase and vitamin К cycle 
Carboxylase 
As stated previously, vitamin К acts as a cofactor for the microsomal 7-glutamylcarboxy-
lase, which γ-carboxylates Glu residues on the amino-terminal end of vitamin K-
dependent proteins (Fig. 1.1). Some properties of this carboxylase enzyme are re­
presented in Table 1.4 (70). The molecular mechanism of carboxylation is recently 
reviewed by Vermeer (64). 
Table 1.4 Properties of vitamin K-dependent carboxylase. 
Required: vitamin К hydroquinone / vitamin К + NADH 
o2 
co2 
Stimulators: dithiothreitol 
dexamethasone 
Inhibitors: chloro-vitamin К 
warfarin 
Substrates: precursors of vitamin K-dependent proteins 
pentapeptides, eg. Phe-Leu-Glu-Glu-Val/Leu 
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The vitamin K-dependent carboxylase is an integral membrane protein concentrated 
at the luminal side of the rough endoplasmic reticulum (62). A model of the interaction 
of the carboxylase with the precursor-peptides is depicted in Fig. 1.6. 
Fig. 1.6 Model of interaction of the vitamin K-
dependent carboxylase with the precursor form 
of the vitamin K-dependent proteins. The 
carboxylase is an integral membrane protein. One 
domain includes the active site, responsible for 
the y-carboxylation reaction. Another adjacent 
section of the extended substrate binding site is 
a complementary surface to the y-carboxylation 
recognition site (y-CRS) on the propeptide. (From 
Furie & Furie (62), with permission). 
Vitamin К cycle 
The energy to drive the carboxylation reaction is provided solely by oxidation of 
reduced vitamin К (KH2) to vitamin K-2,3-epoxide (КО), see Fig. 1.7. Vitamin К 
epoxidase and carboxylase activities are coupled. Subsequently КО can be recycled to 
vitamin К (К) by vitamin K-epoxide reductase. This enzyme is dithiothreitol (DTT)-
dependent in vitro and is inhibited by warfarin. The physiological counterpart of DTT 
has not been identified yet. The cycle is completed by reduction of К to KH 2 by a 
reductase. Several enzymes have been shown to be able to perform this reduction. One 
is DTT-dependent and sensitive to warfarin, hence it may be identical to vitamin K-
epoxide reductase (64, 70). Other reductases are NAD(P)H-dependent and are 
relatively insensitive to warfarin. In other words, during coumarin anticoagulation the 
recycling of КО is blocked, and the supply of KH 2 is rapidly exhausted. However, 
exogenous vitamin К can still be reduced to KH2 by the NAD(P)H-dependent 
reductases. Therefore, high doses of extra vitamin К can be used to bypass the 
blockade and act as an antidote to coumarin intoxication. Under these conditions KHj 
can only be used once, resulting in an accumulation of КО in the liver and plasma (16, 
50). 
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NMTT-cephalosporins or NMTT (N-methyl-thiotetrazole) alone are also thought to 
be inhibitors of hepatic vitamin K-epoxide reductase (71) and hence can induce vitamin 
К deficiency. 
The importance of the vitamin K-cycle being operative in vivo is demonstrated by the 
fact that on a molar basis urinary Gla-excretion exceeds the dietary intake of vitamin 
К 200-500 times. Each molecule of vitamin К must be recycled several thousand times 
before it is metabolized into inactive degradation products (16). 
Fig. 1.7 Vitamin К cycle. Vitamin К hydroquinone (KH^ is oxidated by vitamin К 
epoxidase (1) to vitamin K-2,3-epoxide (КО), while Glu is carboxylated to Gla. KO can 
be reduced by vitamin K-epoxide reductase (2A) in vitamin К quinone (K). This enzyme 
is Warfarin sensitive (W+). К can be reduced back to KH2 by multiple reductases (2B/3). 
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Neonatal carboxylase-system 
Wallin (72) reported data on maturation of the carboxylation system in fetal and 
neonatal rat liver microsomes. The system exhibited low γ-carboxylation activity before 
birth. Around the time of birth there was a 1.5 fold increase in the carboxylation of 
synthetic peptide Phe-Leu-Glu-Glu-Leu. In 2-day-old rats carboxylase activity dropped 
to 50% of activity measured at birth, but in 7-day-old rats activity had risen again to 
a level that was 2.5 fold higher than adult levels. This 'dip' in activity found in 2-day-
old rats coincided with a similar dip for carboxylation of endogenous protein substrates 
and a lower prothrombin precursor concentration in the livers of these rats. Thus, all 
parameters measured suggest that a less efficient carboxylase system exists shortly after 
birth. This may be related to the prolonged prothrombin time 2-3 days after birth in 
human neonates. At birth vitamin K-dependent coagulation factors are about 40-60% 
of adult values (73), due to immature production. However, the presence of PIVKA-
II in neonatal blood cannot solely be due to hepatic immaturity, as administration of 
vitamin К at birth resulted in a significant decrease in the detection of PIVKA-II at the 
age of 3 and 5 days (74). A combination of vitamin К deficiency and hepatic imma­
turity must be responsible for the appearance of PIVKA-II in neonatal blood. 
While carboxylase activity reached adult levels in 7-day-old rats, the activities of the two 
pathways that provide carboxylase with reduced vitamin KH2 cofactor (vitamin К 
reductase and vitamin K-epoxide reductase) were never as high as in adult liver (72). 
For this reason, it might be hypothesized that an increased requirement of vitamin К 
exists in early infancy, due to immature re-utilization of vitamin K-epoxide. 
Wallin also reported that dexamethasone stimulated carboxylase activity 6 days after 
injection of the drug in newborn rats (75). Currently, the available knowledge about 
regulation of the carboxylase system is limited. 
1.7 CLINICAL MANIFESTATIONS OF VITAMIN К DEFICIENCY • 
HAEMORRHAGIC DISEASE OF THE NEWBORN 
Vitamin К deficiency in infancy can cause haemorrhagic disease of the newborn 
(HDN), of which three patterns have been differentiated: early HDN, classic HDN and 
late HDN (see Table 1.5) (76, 77); 
1.7.1 Early haemorrhagic disease of the newborn 
Early haemorrhagic disease occurs at the time of delivery or during the first 24 hours 
after birth. They are often life-threatening. The extent of bleeding varies from skin 
bruising or umbilical bleeding to widespread and fatal intracranial, intrathoracic and 
intra-abdominal haemorrhage. This disease is almost confined to neonates whose 
mothers have taken drugs that affect vitamin К metabolism (78,79,80). It was hypothe­
sized that these drugs, eg. barbiturates, phenytoin, carbamazepine, isoniazid and rifam-
picin, cause induction of microsomal enzymes in the fetal liver and hence accelerate 
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degradation of vitamin К (81). The exact risk for this complication is unknown. 
Mountain et al. (82) reported clinical bleeding tendency in 12.5% of fullterm neonates 
born to mothers on anticonvulsants, while 50% had abnormal coagulation tests. In the 
survey of Deblay et al. (83), 7% of neonates exposed antenatally to anti-epileptic drugs 
had severe internal bleedings and 27% had subnormal prothrombin assays. 
Table 1.5 Classification of haemorrhage disease of the newborn. 
Age Common bleeding 
site 
Cause 
Early HDN 
Classic HDN 
Late HDN 
0-24 h Cephalhaematoma 
Umbilical 
Intracranial 
Intrathoracic 
Intra-abdominal 
Gastrointestinal 
2-7 d Skin 
Nasal 
Gastrointestinal 
Circumcision 
1-52 wk Intracranial 
Skin 
Gastrointestinal 
Maternal drugs 
coumarins 
anti-epileptics 
antibiotics 
Idiopathic 
Idiopathic 
Maternal drugs 
Idiopathic 
Secondary 
diarrhea 
malabsorption 
1.7.2 Classic haemorrhagic disease of the newborn 
Classic HDN usually presents itself on the 2nd to 7th day of life with gastro-intestinal, 
nasal, skin and circumcision bleeding. Most cases are idiopathic. Breast-feeding is an 
important pathogenetic factor (84). Estimates of the incidence of classic HDN prior 
to the initiation of routine vitamin К prophylaxis vary widely. An incidence as high as 
1.7% in full-term infants has been reported (84). Other estimates are somewhat lower, 
ranging from 1:200 to 400 in term neonates (76). 
1.73 Late haemorrhagic disease of the newborn 
Late HDN is observed after the first week of life, predominantly during weeks 3 to 
8. Intracranial haemorrhage accounts for at least half of the bleeding episodes (77, 85). 
Mortality is more than 30% and those who survive frequently suffer from severe 
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neurological sequelae. In one series, vitamin К deficiency was the major cause of 
intracranial haemorrhage in infants after the first week of life, leading to death or 
severe neurological sequelae in 75% of these patients (86). Late HDN is almost 
confined to exclusively breast-fed infants (77, 85, 86). The male : female ratio is 
approximately 1:2 (85). The incidence is particularly high in the Far East. In a survey 
in Japan the incidence of late HDN was found to be 1:3500 in unselected infants and 
1:1700 in breast-fed infants (86). In the former Federal Republic of Germany an 
incidence of 1:27,000 infants who had not received vitamin К prophylaxis at birth was 
calculated (85). In the British Isles a recent two year prospective study revealed an 
incidence of 1:22,000 (87). 
Late HDN may be idiopathic or occur as a secondary manifestation of an underlying 
disorder, like diarrhea, cystic fibrosis, biliary atresia, aj-antitrypsin deficiency, hepatitis, 
a-beta-lipoproteinaemia, coeliac disease, and chronic exposure to coumarin-derivatives 
(76). In 550 case-reports, 189 cases (34%) had other risk-factors, including vomiting, 
jaundice and antibiotic therapy (88). HDN may be the initial manifestation of serious 
underlying disease (76). Aetiology of idiopathic late HDN is unknown. Some 
contributing factors previously discussed are: 
- dietary deficiency of vitamin К (1.4.2) 
- subclinical fat malabsorption (1.5.1) 
- disturbed bacterial gut colonisation (1.5.1) 
- diminished liver stores of vitamin К (1.5.3) 
- immature or impaired carboxylase system in the liver (1.6.3). 
It is likely that a combination of different factors which reduce the ability of babies 
either to absorb or to utilize the vitamin are responsible for late HDN. 
1.8 TREATMENT OF HAEMORRHAGIC DISEASE OF THE NEWBORN 
An infant suspected of having vitamin К deficiency-haemorrhage should be treated 
immediately with 1 mg vitamin K^  while awaiting laboratory confirmation. Except from 
conventional coagulation tests, PIVKA-II should be determined. Due to a long 
disappearance time PIVKA-II can be detected in plasma hours after correction of the 
deficiency and therefore can confirm diagnosis after treatment has been initiated. Even 
in the instance of minor bleedings vitamin K; should be administered, to prevent 
progression of the deficiency with the hazard of intracranial haemorrhage. When the 
deficiency is severe, it may be prudent to administer the vitamin intravenously, because 
intramuscular injection may be associated with haematoma formation and delayed 
absorption. Intravenous injection should be given slowly, since cases of anaphylactoid 
reactions after rapid injection have been reported in adults (89). The coagulopathy is 
usually corrected within a mere few hours, since the pool of noncarboxylated precursors 
is readily carboxylated and excreted after the resurgence of vitamin К (see 1.6.1). For 
life-threatening haemorrhage, parenteral administration of vitamin Kj should be 
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followed by 10 to 20 ml/kg of fresh-frozen plasma, to increase the levels of vitamin K-
dependent factors immediately. Administration of prothrombin complex concentrates 
(PPSB; concentrates of factors II, VII, IX and X) is rarely needed and has the 
potential risk of viral infection. 
The use of vitamin K; (Phytomenadione) in infancy is safe. Doses as high as 10 to 25 
mg have not been associated with toxic symptoms or hyperbilirubinaemia (5). The use 
of menadione (vitamin Kj) or its water-soluble derivatives, however, is obsolete, since 
it may cause haemolytic anaemia and subsequent hyperbilirubinaemia and kernicterus 
in the neonate (8). 
1.9 CURRENT CONTROVERSIES ABOUT PREVENTION OF VITAMIN К 
DEFICIENCY 
1.9.1 Safety of vitamin К prophylaxis 
Although no serious side effects have been reported so far despite widespread use of 
vitamin K, some concern exists about the innocence of vitamin К administration to 
young infants. Israels et al. (90) have reported that increased levels of vitamin Kj 
enhance the mutagenic and carcinogenic effect of benzopyrenes in mice. They also 
reported an increase in sister chromatid exchanges (SCE) in lymphocytes after in vitro 
and in vivo exposure to vitamin K; (91). The authors concluded that maintaining 
vitamin K.J at a cellular concentration just sufficient to meet the needs of the 
carboxylase system, presents a biological advantage to the fetus by reducing the risk of 
mutagenic events. Conversely, vitamin Ky was found to be non-mutagenic in the Ames/ 
Salmonella typhimurium mutagenicity test (92). Golding et al. (93) unexpectedly 
discovered a statistical association between childhood cancer and vitamin К administra­
tion (among other drugs) in the first week of life. This concern with a possible 
genotoxic or carcinogenic risk of the administration of vitamin К during early life 
should not be neglected; further studies are needed. In chapter 3 this problem is 
discussed more extensively, in combination with own results of mutagenicity tests of 
vitamin К prophylaxis in the human neonate. 
1.9.2 Classic haemorrhagic disease of the newborn 
Vitamin К prophylaxis was introduced to prevent classic HDN and its efficacy has 
been established beyond doubt. Reduction in bleeding episodes (84, 94) as well as 
prevention of neonatal hypoprothrombinaemia (55, 94) have been reported after 
administration of 1-2 mg vitamin Щ at birth. Abandonment of routine vitamin К 
prophylaxis and high rates of breast-feeding have led to a resurgence of HDN in the 
U.K. (95). Currently, many countries recommend vitamin К prophylaxis (96). Neverthe­
less, controversy still exists as to whether all neonates require prophylaxis. Some have 
suggested, partly with the aim of reducing costs, to recommend selective prophylaxis 
in those at risk: low-birth-weight infants, breast-fed infants, infants with inadequate food 
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intake, infants on antibiotics, infants needing surgery, etc. (97). Some children, however, 
develop vitamin К deficiency-haemorrhage without any perinatal risk-factor. In addition, 
a recent cost-benefit analysis revealed that the total costs for the society without a pro­
phylaxis regimen exceed the costs for an oral or intramuscular (i.m.) prophylaxis 
programme (98). It was recommended to adopt the oral route as it is cheaper, is more 
consumer acceptable and has a lower risk of iatrogenic disease (98). Indeed, severe 
neonatal complications after accidental injection of maternal ergometrine and oxytocin 
have been reported (99). On the other hand, there is some debate whether oral and 
i.m. application are comparable. Studies of conventional coagulation tests, vitamin K; 
and PIVKA-II concentrations revealed that oral administration of vitamin К is as 
effective as i.m. injection in the prevention of classic HDN (45,55,94,100,101,102). Dunn 
(103) recorded no proven case of classic HDN in 31,000 newborns given 1 mg vitamin 
Ky with their first feed. Whether oral vitamin К prophylaxis at birth is also capable of 
preventing late HDN will be discussed in the next paragraph. 
1.9.3 Late haemorrhagic disease of the newborn 
Whether prophylactic measures designed to protect against classic HDN are able to 
prevent late HDN has been questioned with respect to the short plasma half-life of 
vitamin K.J. The plasma half-life, however, is irrelevant with respect to liver stores, 
which have been reported to remain elevated for at least 2 weeks after an i.m. admin­
istration at birth (see 1.5.3). Clinical experience suggests that parenteral vitamin К 
prophylaxis at birth offers some protection against late HDN since most case-reports 
concern breast-fed children whithout prophylaxis (77). Nevertheless, several cases of 
late HDN have been reported despite vitamin К prophylaxis at birth (Table 1.6). 
It seems to be that failures are more frequent after oral than after i.m. application of 
the vitamin at birth, but this must be corrected for the relative frequency of oral 
administration compared to i.m. injection. Hathaway et al. (104) compared oral and i.m. 
prophylaxes at the age of 4 weeks and concluded that a single dose of vitamin К 
prevents most instances of late HDN. However, vitamin К prophylaxis should prevent 
all cases of HDN. Isarangkura et al. (105) reported that 1 mg i.m. and 2 mg oral doses 
of vitamin K^ increased mean Thrombotest values up to the age of 2 months, while the 
effect of a 1 mg oral dose was limited to 1 month. Others, however, dispute the need 
for any vitamin К supplementation (106). 
Alltogether, the discussion about the best route of administration of vitamin К and 
whether repeated administrations are needed in breast-fed infants is still ongoing. Pros­
pective studies evaluating different regimens of vitamin К prophylaxis are lacking. In 
this thesis 3 such studies are reported (chapters 4, 5, and 6) comparing oral and i.m. 
administration and evaluating a weekly and daily regimen of vitamin К prophylaxis for 
breast-fed infants. 
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Table 1.6 Failures of oral and Lm. vitamin К prophylaxis at 
birth, resulting in late HDN. 
Author 
Verity 1983 
Chaou 1984 
Chanvitan 1986 
Matsuzaka 1987 
Priestley 1987 
Hanawa 1988 
Sutor 1988 
Tönz 1988 
Kries 1988 
Lange 1988 
Matsuda 1989 
Matsuzaka 1989 
Hanawa 1990 
Göbel 1991 
Sutor 1991 
McNinch 1991 
Ekelund 1991 
(Reí) 
(107) 
(108) 
(109) 
(86) 
(110) 
(111) 
(112) 
(113) 
(114) 
(115) 
(49) 
(116) 
(117) 
(118) 
(85) 
(87) 
(119) 
Or 
1 
1 
18 
1 
8 
3 
1 
1 
2 
26 
3 
4 
7 
17 
Total cases 93 11 
1.9.4 Early haemonrhagic disease of the newborn 
More than 40 case-reports have been published on neonatal haemorrhage in infants 
bom to mothers treated with anti-epileptic drugs which induce liver enzymes (79). 
Most of the neonates had not received vitamin К prophylaxis at birth, although some 
had (79). A fatal case despite prompt i.m. administration of vitamin К at birth and 
additional doses at the onset of bleeding, has been reported (120). Since women with 
epilepsy account for approximately 0.5% of all pregnancies (121), clear guide-lines for 
prevention of this disease should be available. Maternal ingestion of 20 mg vitamin K; 
during the last 2 to 4 weeks of pregnancy has been proposed (79,82,121) and was 
found to prevent neonatal hypoprothrombinaemia in a preliminary study (83). 
Alternatively, vitamin K^ can be administered intravenously to the mother during labour 
(79,82,120). Complicating aspects of transplacental transport have been discussed in 
paragraph 1.5.2. Another suggestion for prevention of early HDN is to change the 
treatment of pregnant women with epilepsy to drugs that are not enzyme-inducive, such 
as clonazepam (79). In this thesis first an observational study is reported, to establish 
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the incidence of (biochemical) vitamin К deficiency in mothers and neonates exposed 
to anticonvulsant therapy (chapter 7), and secondly a case-control study evaluating the 
effects of daily supplementation of 10 mg vitamin Kj during the last month of preg­
nancy (chapter 8). 
1.10 AIM OF THE STUDY 
Vitamin К deficiency is associated with HDN, which may be fatal or cause serious 
morbidity. After having studied the detection and incidence of vitamin К deficiency in 
normal infants (thesis Widdershoven, 122), our group was interested in the prevention 
of vitamin К deficiency. At that time vitamin К prophylaxis was not uniformly practised 
in the Netherlands or abroad due to many controversies. 
The aim of this thesis is to provide some answers to the following questions concerning 
appropriate vitamin К prophylaxis for young infants: 
1. Is the administration of 1 mg vitamin Kj i.m. at birth genotoxic? (chapter 3) 
2. Is i.m. administration more effective than oral administration? (chapter 4) 
3. Does vitamin К prophylaxis at birth prevent late HDN? (chapter 4) 
4. What is the optimal mode of vitamin К supplementation for breast-fed infants 
after the neonatal period, in order to prevent late HDN? (chapters 5 and 6) 
5. Can early HDN be prevented by administration of vitamin K; to the mother 
prenatally? (chapters 7 and 8) 
In other words, what is the best recommendation for prevention of vitamin К deficiency 
and thereby haemorrhagic disease of the newborn? 
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2. LABORATORY PARAMETERS FOR 
VITAMIN К DEFICIENCY 
2.1 CONVENTIONAL COAGULATION TESTS 
The diagnosis of vitamin К deficiency is suggested if decreased concentrations of 
vitamin K-dependent coagulation factors normalize after vitamin К administration. 
However, in full-term neonates normal levels of these factors are about 40-60% of 
adult values (1). In preterm neonates the levels are even lower, about 25-60% of 
adult values and they are further decreased when hypoxia or respiratory distress syn­
drome is present (2). After birth, concentrations of factor VII rise to near adult 
values in 5 days, but factors II, IX and X only reach adult values after 3 to 6 
months. The vitamin K-dependent coagulation inhibitors proteins С and S are about 
35% of adult values at birth. Protein С is still markedly low at 6 months of age. In 
clinical bleeding from vitamin К deficiency, levels of vitamin K-dependent clotting 
factors are usually below 15%. 
Measurement of vitamin K-dependent coagulation factors or screening tests re­
flecting the levels of vitamin K-dependent factors such as prothrombin time (PT), 
partial thromboplastin time (PTT) and thrombotest (TT), are not sensitive enough 
to detect mild vitamin К deficiency (3). In this thesis, apart from TT and activities 
of factors VII and X, abnormal des-carboxy-prothrombin (PIVKA-II) and vitamin K, 
concentrations were used to assess vitamin К status. 
Thrombotest 
ТГ, which reflects activities of factors II, VII and X and is sensitive to PIVKA, was 
performed according to the method of Owren (4), using Thrombotest Reagents 
(Nyegaard & Co, Oslo, Norway). 
Assays for clotting factors VII and X 
Activities of factors VII and X were measured by chromogenic substrate assays, 
using commercially available test-kits (Coa-set FVH and Coatest FX, Kabi Diagnos­
tica, Mölndal, Sweden). Determination of factor VII is based on a two-stage 
principle. In stage one factor X is activated to Xa via the extrinsic pathway by 
factor VII and Tissue Factor (Fig. 1.5). During this proces factor VII is completely 
converted to Vila. In stage two the generated factor Xa hydrolyses the chromogenic 
substrate, thus liberating the chromophoric p-nitroaniline. The colour is read 
photometrically at 405 nm. The determination of factor X is based on a single step 
assay, in which factor X is activated by Russell's Viper Venom. 
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2.2 PIVKA-II DETERMINATION 
The determination of uncompletely carboxylated coagulation factors (PIVKA) is 
suitable to detect biochemical vitamin К deficiency (3). Different methods are 
available to determine PIVKA-II. In one method the ratio between factor II 
activated by physiological activators (IIUCi) and factor II activated by viper's venom 
(IIfl„) is used. Because the latter activates both normal and abnormal factor II, a 
clear difference, defined as ratio I I
a c i / ІІа_ < 0.86, indicates vitamin К deficiency. 
Other methods use adsorption of native prothrombin, electrophoresis or antibodies 
specific to PIVKA-II. Widdershoven et al. (5) compared four methods to determine 
PIVKA-II and concluded that direct detection by monoclonal antibody was the most 
sensitive method. This method was found to be fine to study the incidence of sub­
clinical vitamin К deficiency and the effect of different prophylactic regimens on this 
incidence (5). 
PIVKA-II assay in this thesis 
Monoclonal antibody against PIVKA-II was prepared by Motohara et al. (6). This 
antibody quantitatively reacts with PIVKA-II and does not cross-react with native 
prothrombin. The antibody has a higher affinity to PIVKA-II possessing less Gla 
residues. A sandwich enzyme-immuno assay (EIA) was established (Eitest mono P-II 
kit, Eisai Co, Tokyo, Japan). In this assay the wells of a polyvinyl microplate are 
coated with the monoclonal antibody. Standard antigen solutions and 100 μ] of the 
test samples are added to the cups and incubated overnight at 4CC. After washing 
100 μΐ of peroxidase-labelled antihuman prothrombin anti-IgG is added to the wells 
and incubated for 1 hour at 40C. After washing again, peroxidase activity of the 
immunocomplexes fixed onto the cups is assayed with 2,2'-azino-bis-(3-ethyl-benzo-
thiazoline-6-sulfonic acid) as a chromogen. After stopping the reaction the colour is 
measured by spectrophotometry at 405 nm. 
The results are expressed in arbitrary units (AU); 1 AU corresponds to 1 /ig of 
purified prothrombin. The limit of detection is the PIVKA-II level obtained when 
the difference between the absorbance of the specimen and the blank is 15 mAbs. 
The detection limit was 0.10 AU/ml. Recovery of PIVKA-II added to normal plasma 
was 101 ± 9%. 
PIVKA-II levels in 50 healthy adults, 13 pregnant women and 67 adults with liver 
cirrhosis were all below 0.10 AU/ml, which was considered as the upper normal 
limit (7). PIVKA-II values higher or lower than 0.10 AU/ml were defined as positive 
or negative, respectively (7). In three infants with intracranial haemorrhage caused 
by vitamin К deficiency, PIVKA-II amounted to very high levels of about 50 AU/ml 
(6). In adults receiving warfarin PIVKA-II levels ranged from 3 to 43 AU/ml (6). 
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The plasma half-life of PIVKA-II in adults was reported to be 60 hours (7, 8), 
though others reported a shorter half-life of about 20 hours (9, 10). This long 
disappearance time of PIVKA-II allows detection of vitamin К deficiency after the 
deficiency itself has been corrected. 
23 VITAMIN K¡ DETERMINATION 
By high-performance liquid chromatographic (HPLC) separation vitamin K; can be 
determined. Early studies used ultra-violet detection to quantify the vitamin. 
Recently, more selective and sensitive detection techniques have been developed, 
e.g. electrochemical reduction, mass spectrometric detection and fluorescence 
detection after electrochemical or chemical reduction. 
In this thesis the method developed by Lambert et aL (11, 12) was applied, involving 
post-column chemical reduction and fluorescence detection. Vitamin K ^ j i , which 
was kindly supplied by Hoffmann-La Roche, was used as internal standard (IS). All 
sample manipulations were performed in the absence of daylight and by use of low 
actinic (brown) glassware to prevent isomerization and photodegradation of the К 
vitamins. Information about the equipment used is stated in paragraph 4.3. 
Consecutive steps in the determination of trans-vitamin Kj were as follows; 
(see Fig. 2.1) 
1. Addition of a defined amount of internal standard (IS). 
2. Denaturation of proteins by ethanol. 
3. Extraction of vitamin K^ and IS by hexane. 
4. Pre-separation on the first HPLC system by a silica column (100 χ 4.6 mm, 
Microspher-SI, Chrompack, the Netherlands). 
5. Collection of the effluent fraction containing vitamin K; as well as IS. 
Retention times of these vitamins were determined daily by injecting stand­
ards which could be monitored by UV detection. Fractions were usually col­
lected between 3.0 and 5.5 min. 
6. Separation on the second HPLC system by reversed-phase column (100 χ 
4.6 mm, Microspher-C18, Chrompack). 
7. Chemical reduction. The reductive agent (tetramethylammoniumoctahydrido-
triborate) was already added to the eluent of the second HPLC system. On 
line post-column reduction was performed at the high temperature present 
in the knitted-coil-reactor situated in an oil-bath set at 850C. Each day the 
first runs were performed with standards to check the reduction process. 
8. Fluorescence detection at an emission-wavelength of 450 nm after excitation 
at 325 nm. An example of a chromatogram is depicted in Fig. 2.2. 
9. Calculation of vitamin K; concentration by measurement of fluorescence 
peak-heigth of vitamin K; hydroquinone and correction for peak-height of 
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IS. The correlation coefficient between corrected peak-heights and known 
amounts of vitamin K.¡ added to plasma or water is 0.9985. After calibration 
with known amounts of vitamin Kj, next equation was found for calculating 
vitamin Ky concentrations: 
peak-height K. 
(( ) χ 100 χ 17.626) - 24.93 
peak-height IS 
Recovery of vitamin Kj added to normal serum in four different concentrations was 
85 ± 5%. The minimal detection limit was 45 pg/ml at a signal-to-noise ratio of 3. 
However, the detection limit of individual samples can vary, dependent on the 
recovery of IS during extraction and on the amount of serum extracted. Within-day 
coefficient of variation was calculated 2.2 ± 1.0% (n=6, x=1250 pg/ml). Day-to-day 
coefficient of variation was 3.9% (n=24, x=1250 pg/ml). 
Fig. 2.2 Representative chromatogram of a serum extract. Peak identification: 
(1) vitamin АГ;^ 20,, concentration 2657 pg/ml; (2) vitamin Kj^j, used as internal 
standard. 
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Fig. 2.1 Schematic representation of vitamin Kj determination. 
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3.1 ABSTRACT 
In many countries vitamin К prophylaxis at birth is recommended in order to 
prevent bleeding in infants due to vitamin К deficiency. Because the incidence of 
clinical vitamin К deficiency is very low, such a vitamin К administration should be 
completely safe. However, an increase in sister chromatid exchanges in lymphocytes 
of fetal sheep 24 hours after injection of vitamin K^  has been reported. Therefore, a 
study concerning genotoxicity of vitamin Kj in man was conducted. Sister chromatid 
exchanges and chromosome aberrations were analysed in peripheral blood lympho­
cytes of 6 newborns 24 hours after intramuscular administration of 1 mg vitamin K^ 
and in 6 control neonates. The mean number of sister chromatid exchanges per 
metaphase in the vitamin К group was 8.88 ± 1.22 as compared with 9.05 ± 1.14 in 
the control group (NS). The mean number of chromosome aberrations per 100 
mitoses was 3.00 ± 2.61 in the vitamin К group and 2.50 ± 1.87 in the control 
group (NS). Vitamin K^ plasma concentrations ranged from 115 to 1150 ng/ml (255 
to 2555 χ W9 M) in the supplemented group, a 5000-fold rise as compared with the 
control group (p<0.01). We did not find any evidence for genetic toxicity due to the 
administration of 1 mg vitamin Kj intramuscularly to the newborn child. 
3.2 INTRODUCTION 
The problem of bleeding in infants due to vitamin К deficiency has been recognized 
worldwide. In many countries vitamin К prophylaxis at birth is recommended to 
prevent this hazard. Introduction of such a prophylaxis appeared to have spectacular 
results on the incidence of this so-called Haemorrhagic Disease of the Newborn (1). 
Because the incidence of clinical vitamin К deficiency is very low, this vitamin К 
supplementation should be completely safe. However, in 1987 Israels et al. (2) 
reported a dose-dependent increase of the frequency of sister chromatid exchanges 
(SCE) in lymphocytes after in vitro exposure to vitamin Kj. In vivo exposure, tested 
in five fetal sheep given 1 mg of vitamin Κγ i.V., also resulted in an increase in SCE 
24 hours after injection. SCE represent interchanges of DNA at apparently homo­
logous chromosomal sites after replication. These exchanges presumably involve 
DNA breakage and reunion. Although there is no perfect agreement between the 
ability of a compound to produce SCE and its mutagenicity or carcinogenicity, there 
is a high degree of correlation (3). Israels et al. (2) postulated that the relative 
vitamin К deficient state of the newborn may in fact play a role in the protection of 
the fetus in utero by reducing the risk of mutagenic events during this period of 
rapid cell proliferation. The question arises whether the results of the study of 
Israels et al. indicate a genotoxic or carcinogenic risk to man, specifically when the 
vitamin is administered during early life. Moreover, Golding et al. (4) reported a 
statistical association between childhood cancer and vitamin К administration 
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(among other drugs in the first week of life). This association was found unexpec-
tedly and fitted no prior hypothesis. The need for further research was stressed by 
the authors. To our knowledge, cytogenetic studies concerning genotoxicity of 
vitamin Kj in man have as yet not been performed. 
Apart from SCE assays, another way of testing for cytogenetic mutagenicity is to 
analyse chromosome aberrations (CA). CA reflect damage of the chromosome- or 
chromatid-type and can be observed as breaks, acentric fragments, minutes, ring 
chromosomes, and gaps. Gaps are defined as regions in the chromatid structure that 
are achromatic, thus, the chromosome structure is not really discontinued (5). 
Because CA and SCE are two different cytogenetic end points of mutagenic action, 
they are complementary (6). Neither CA nor SCE have been studied before in 
human neonates exposed to vitamin K¿. 
The aim of this case-controlled clinical trial is to determine whether the administra-
tion of 1 mg vitamin Kj i.m. after birth influences the occurrence of SCE and CA 
in cultured peripheral blood lymphocytes. 
33 METHODS 
Subjects 
The study was approved by the local medical ethical committee. Informed consent 
was obtained from the parents. Twelve healthy breast-fed newborns, born in our 
hospital, were recruited for this study. Selection criteria were delivery at term (37-42 
wk), birth weight over 2500 g, and Apgar score at 5 min of seven or more. The 
mother could not be on a special diet, smoke, abuse alcohol, or take any medication 
during the last month of pregnancy, except for iron or folic acid. Arterial cord blood 
pH, mode of delivery, and medication of the mother during labour were recorded. 
All infants had an arterial cord blood pH over 7.24, except for subject 7, who had a 
pH of 7.17. All children were born vaginally, except for subject 1 who was born by 
Caesarean section. In two cases oxytocin was given to the mother during labour 
(subjects 3 and 11). 
The infants were randomly divided into two groups; six received 1 mg vitamin Kj 
i.m. (Konakion^, Hoffmann-La Roche), the other 6 received no medication. Some 
characteristics of the neonates are given in Table 3.1. No item differed significantly 
between the groups. After 24 hours 5 ml of blood were drawn by aseptic venepunc-
ture: 2 ml of heparinized blood and approximately 3 ml of blood with no additive. 
The latter was kept in the dark immediately after sampling, centnfuged (1000 χ g 
for 5 min), and stored at -20^ until vitamin Kf determination. All samples were 
coded to provide blind cytogenetic analysis. 
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Table 3.1 Study population characteristics (mean ± SD). 
Number 
Male : female 
Gestational age (wk) 
Birth weight (g) 
Apgar score at 5 min 
Arterial cord blood pH 
Age at venepuncture (h) 
Vitamin К 
6 
2 : 4 
39.5 ± 1.8 
3338 ± 608 
8.8 ± 1.2 
7.27 ± 0.03 
24.6 ± 0.4 
Control 
6 
3 : 3 
40.4 ± 0.7 
3817 ± 299 
9.7 ± 0.5 
7.29 ± 0.09 
27.8 ± 5.8 
Vitamin Ky 
Vitamin K; was measured in 1 ml serum samples by a two-step HPLC procedure, 
according to the method of Lambert et al. (7, 8). A few modifications were applied. 
The assays were performed with two Spectra Physics SP8800 systems (Spectra 
Physics, Santa Clara, USA) equipped with Rheodyne 7125 manual injectors (Rheo-
dyne, Colati, USA), with 100 μ\ sample loops. Vitamin Щпі) w a s u s e c ' a s a n 
internal standard. The first HPLC step was used for pre-separation of vitamin K^  
and Kw25) o n a microspher-Si column (Chrompack, Middelburg, the Netherlands). 
The locations of vitamin Kj and internal standard were detected with a variable 
wavelength detector model 770 (Spectra Physics) set at 248 nm. Final separation 
and quantification were performed during the second HPLC step, using a micro-
spher-C18 column (Chrompack) for separation and post-column chemical reduction 
with tetramethylammonium-octahydridotriborate for fluorescence detection (λ£ Ι= 
325nm, X
em
=450 nm) with a Waters 470 fluorescence detector (Waters, Millipore 
Corp., Milford, USA). Concentrations were calculated from relative peak heights of 
vitamin Ky versus known amounts of internal standard. The lower limit of detection 
was 0.045 ng/ml; however, the detection limit is dependent on the recovery of 
internal standard and the amount of serum extracted. 
Cytogenetics 
Peripheral lymphocyte cultures were initiated within two hours after blood collection. 
For each culture two containers with medium (8 ml RPMI 1640 medium, supple­
mented with 15% fetal calf serum, heparin, phytohemagglutinin, penicillin and 
streptomycin) were each supplied with 0.2 ml neonatal whole blood. From all infants 
two cultures were set up: one with and the other without bromodeoxyuridine (BrdU, 
final concentration 10 /tg/ml). BrdU was present in the medium during the whole 
culture period. All cultures were grown in the dark at 370C for exactly 72 hours. 
Colcemid (final concentration 0.2 Mg/ml) was added 90 min before harvesting. 
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Chromosome spreads were made according to routine procedures. The standard 
cultures without BrdU were applied for aberration screening by one technician. 
From every child 100 mitoses were studied after conventional Giemsa staining and 
all CA were recorded and photographed. The cultures with BrdU were used for 
SCE studies. From every infant 25 complete mitoses were photographed in fluor­
escence microscopy after the chromosomes had been stained with acridine orange 
(9). In this way the number of SCE could easily be counted from the photograph. 
Statistics 
For statistical evaluation the unpaired t test was applied for study-population 
characteristics, SCE, and CA results. Vitamin Kj concentrations were compared by 
Wilcoxon's two-sample test. All values are given as means ± SD. 
3.4 RESULTS 
The vitamin K; concentrations and the number of SCE and CA of each subject are 
presented in Table 3.2. The SCE results are missing for subjects 4 and 8 because of 
insufficient growth of BrdU cultures. Less than 20 mitoses were suitable for SCE 
analysis. Conventional growth was adequate and CA were counted. During deter­
mination of vitamin K; in subject 4, a technical error was encountered. Because of 
the small volumes of serum available from the neonates, the procedure could not be 
repeated. 
Twenty-four hours after injection of 1 mg vitamin Kj, plasma concentrations ranged 
from 114.6 to 1150.5 ng/ml (255 to 2555 χ IO'9 M). Vitamin К; concentrations in 
the supplemented group were raised some 5000-fold as compared with the control 
group (p<0.01). In two subjects of the control group, the vitamin Kj concentration 
was not even detectable. Because of differences in volume of serum available, the 
detection limit ranged from 0.045 to 0.198 ng/ml in these samples. 
In the vitamin К supplemented group, the mean number of SCE was 8.88 ± 1.22 
per metaphase compared with 9.05 ± 1.14 in the control group. The groups did not 
differ significantly (p=0.82). 
When the total number of chromosome and chromatid breaks as well as gaps was 
taken into account, a mean number of 3.00 ± 2.61 CA per 100 mitoses was 
detected in the vitamin К group. In the control group a mean number of 2.50 ± 
1.87 per 100 mitoses was found. (NS, p=0.71). When gaps were excluded, the mean 
numbers amounted to 1.50 ± 1.05 and 2.50 ± 1.87, respectively. Still, no significant 
difference was present (/7=0.28). 
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Table 3.2 Number of sister chromatid exchanges (SCE) and chromosome aberrations 
(CA) in metaphases of cultured lymphocytes of newborns who did or did not receive 
1 mg vitamin K¡ i.m. after birth. 
Subject n2 
VITAMIN К 
1 
2 
3 
5 
8 
11 
mean 
25 
24 
26 
20 
— 
24 
23.8 
CONTROL 
4 
6 
7 
9 
10 
12 
mean 
« 
20 
21 
24 
29 
25 
23.8 
SCE 
mean 
9.96 
7.96 
8.03 
10.45 
— 
8.00 
8.88 
-
10.30 
8.52 
7.80 
8.41 
10.24 
9.05 
SD 
2.92 
2.46 
3.13 
3.68 
— 
2.67 
2.97 
-
2.92 
2.69 
2.77 
2.10 
3.20 
2.74 
chrbr 
0 
0 
0 
0 
0 
2 
0.33 
0 
0 
0 
1 
1 
0 
0.33 
CA' 
chrmatbr 
1 
0 
2 
3 
1 
0 
1.17 
2 
6 
1 
2 
0 
2 
2.17 
gap 
0 
0 
5 
0 
4 
0 
1.5 
0 
0 
0 
0 
0 
0 
0 
Vit К ; 
(ng/ml) 
114.6 
203.9 
545.0 
443.4 
1150.5 
757.4 
535.8 
— 
0.188 
< 0.045 
0.130 
0.132 
<0.198 
-
1, per subject 100 mitoses were screened. 
2, number of cells investigated for SCE. 
--, missing value (see text). 
chrbr, number of chromosome-breaks; chrmatbr, number of chromatide-breaks. 
3.5 DISCUSSION 
As would be expected, 24 hours after the administration of 1 mg vitamin Ky i.m. 
serum concentrations vitamin Kj were extremely high, the mean being 536 ng/ml. 
This finding is in accordance with the reported mean values of 444 ng/ml by Mc 
Ninch et al. (10) and of 348 ng/ml by Lucock et al. (11). Mc Ninch et al. (10) 
detected a peak concentration of 1781 ng/ml after 12 h. This shows that the blood 
lymphocytes in the vitamin К group certainly have been exposed to extremely high 
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concentrations of vitamin К before sampling. Previous studies have shown that the 
plasma concentration declines rapidly (12). 
Several short-term mutagenicity test sytems have been developed to identify agents 
which can adversely affect the genetic material of cells (The American Industrial 
Health Council, 13). This property may indicate the potential for a number of 
adverse effects, one of which is carcinogenicity. There is a clear and justifiable 
rationale for the use of genetic toxicology assays, but they are less than perfect. 
Accuracy, which is a combination of sensitivity and specificity, is about 60%. 
Therefore, one assay will be insufficient (13, 14). The Ames/Salmonella typhimurium 
assay is the test most commonly used for evaluation of chemicals in vitro (15). 
Vitamin Щ was not mutagenic in this test (16). A negative Ames test, however, 
does not exclude carcinogenicity, inasmuch as a negative predictive value of mere 
51% was calculated (14). In other words, performance of an Ames test alone is 
inadequate to determine whether vitamin K^  is genotoxic. Moreover, Israels et al. 
(2) did report an increase of SCE in lymphocytes after in vitro and in vivo exposure 
to vitamin K^ In vitro exposure was analysed in cultured lymphocytes of human 
placental blood and adult female blood with added vitamin K ; at a concentration of 
1 χ ΙΟ"6 M (450 ng/ml). Consequently, the lymphocytes that were stimulated to 
replicate by phytohemagglutinin were exposed for at least 48 hours to a high 
concentration of vitamin Ky. This is quite different from in vivo situations, where 
high concentrations of vitamin K; are only temporary and lymphocytes normally do 
not divide. In vivo exposure was tested in fetal sheep in utero given 1 mg of vitamin 
K; i.V.. SCE were measured before and 24 hours after injection. Each fetus showed 
an increased number of SCE after vitamin K .^ 
Because the aim of the present investigation was to determine whether there are 
indications that vitamin К may have genotoxic effects in the human neonate, we 
opted for an in vivo study in humans with the intention to reflect the clinical 
situation, especially because several unknown factors may hamper generalization of 
in vitro and animal studies to clinical practice. SCE and CA analyses were per­
formed on cultured lymphocytes after exposure of the neonate in vivo. Accordingly, 
the vitamin will be subjected to the spectrum of activating and deactivating enzymes 
as far as these are developed in the newborn (17). Detoxification or formation of 
toxic degradation products might be different in fetal lambs as compared with 
human neonates. In fetal mice SCE response was found to decline with gestational 
age (18). Administration of mitomycin C, a mutagen that does not require metabolic 
activation, and of cyclophosphamid, a drug activated by the liver into a potent 
alkylating agent, both resulted in a decline in SCE with gestational age. Repair 
capacities may vary with gestational age. 
Fortunately, no carcinogenic metabolites are reported for vitamin Kp In the liver 
vitamin К is first reduced to vitamin К hydroquinone and subsequently oxidized to 
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vitarain K-2,3-epoxide. This oxidation is connected with the carboxylation reaction in 
which glutamic acid residues of vitamin К dependent coagulation factors are 
carboxylated. Subsequently, vitamin K-2,3-epoxide is converted back into natural 
vitamin К and the cycle is complete. In adults vitamin K; is excreted in urine and 
bile as more polar metabolites (carboxylic acids) conjugated with glucuronic acid. An 
enterohepatic circulation is present (19). After supplementation with vitamin Kj 
urinary and faecal excretion is virtually complete after three days and amounts to 
about 60% of the dose (19). Whether fetal vitamin К metabolism differs from adult 
metabolism is unknown but conceivable. 
Besides advantages, in vivo testing carries the problem that unknown confounding 
factors may disturb the conclusions. Age, sex, tobacco smoking, medication, and 
alcohol abuse may be confounders (20). In the present study these items were 
excluded or otherwise randomized. We were unable to detect an increase in SCE 24 
hours after the administration of 1 mg vitamin K ; i.m.. 
Because additional negative results were achieved in the CA analysis, which is a less 
sensitive but more specific short-term mutagenicity test (14), a genotoxic effect is 
improbable. 
When the effects of supplementation with vitamin К are considered, not only 
plasma concentrations (and lymphocyte exposure) have to be taken into account. 
Concentrations in other tissues may differ. It might be possible that because of 
accumulation hepatic concentrations which are higher than plasma concentrations 
are reached. The hepatic concentration of vitamin K¡ in unsupplemented term 
neonates is reported to be about 1 ng/g liver (fresh weight) with a wide range (21). 
This is 10-fold higher than the plasma concentration of about 0.1 ng/ml in our 
control group. Shearer et al. (21) have reported hepatic vitamin K; concentrations 
10 hours after i.m. administration of 0.5 to 1.0 mg vitamin Ky of approximately 200 
ng/g, and after 1 to 4 days of 500-2000 ng/g. These levels are comparable to the 
plasma concentrations in our supplemented group, so there are no indications that 
higher concentrations are reached in the liver than in the blood after a single i.m. 
dose of vitamin K .^ 
In conclusion, as yet there is no evidence for cytogenetic toxicity due to the 
administration of 1 mg vitamin K^ i.m. to the newborn infant. 
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4.1 ABSTRACT 
A randomised clinical trial was conducted to establish the effects of oral and 
intramuscular administration of vitamin К at birth on plasma concentrations of 
vitamin Ky, proteins induced by vitamin К absence (PIVKA-II), and clotting factors. 
Two groups of about 165 healthy breast-fed infants who received at random 1 mg 
vitamin K; orally or intramuscularly after birth, were studied at the age of 2 weeks 
and 1 and 3 months. Although vitamin K^ concentrations were statistically sig­
nificantly higher in the intramuscular group, Thrombotest, activities of factors VII 
and X and PIVKA-II concentrations did not reveal any difference between the two 
groups. At the age of 2 weeks vitamin Kj concentrations were raised as compared 
with reported unsupplemented concentrations and PIVKA-II was not detectable. At 
the age of 3 months vitamin K^ levels were back at unsupplemented values and 
PIVKA-II was detectable in 11.5% of infants. Therefore, a repeated oral prophylaxis 
will be necessary to completely prevent (biochemical) vitamin К deficiency beyond 
the age of 1 month. 
4.2 INTRODUCTION 
Vitamin К deficiency is associated with haemorrhagic disease of the newborn 
(HDN). Three patterns of bleeding have been differentiated: early HDN within 24 
hours after birth, classical HDN on days 1 to 7, and late HDN after the first week 
of life (1). Late HDN is often located intracranial. These haemorrhages may be 
fatal or cause serious morbidity. Breast-feeding has an important role in the 
pathogenesis of classical and late disease (1). Many countries recommend vitamin К 
prophylaxis after birth to prevent this hazard of vitamin К deficiency. Nevertheless, 
there are still controversies concerning the best way of providing an effective 
prophylaxis, resulting in different policies. The safety of oral and parenteral vitamin 
К prophylaxis in the prevention of classical HDN has been established beyond 
doubt, whereas the relationship between a single vitamin К prophylaxis at birth and 
late HDN has not been clearly determined (1, 2). Several studies have indicated 
that oral prophylaxis might be as effective as intramuscular (i.m.) administration, but 
these studies lack follow-up beyond the first week of life (3-5). Epidemiologically, 
i.m. vitamin К prophylaxis appears to have a lower incidence of failure (6-8), 
probably because of the more reliable absorption (4). Oral administration, however, 
has the appealing characteristics that the injury of injection is avoided and that 
administration is simple, resulting in better parental acceptance. 
The aim of this study was to evaluate whether oral administration of vitamin К is as 
effective as i.m. administration in the prevention of vitamin К deficiency beyond the 
first week of life in breast-fed infants. Determination of proteins induced by vitamin 
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К absence (PIVKA-II) was applied to detect biochemical vitamin К deficiency. 
Vitamin К is necessary for production in the liver of coagulation factors II, VII, IX 
and X. The vitamin K-dependent carboxylation of glutamic acid residues to γ-
carboxyglutamic acid residues promotes calcium binding to these proteins which is 
essential for effective haemostatic function. When carboxylation is impaired because 
of deficiency or antagonism of vitamin K, inert precursors of prothrombin (factor II) 
are detected in the blood (9). These are known as PIVKA-II. In formula-fed infants 
and adults PIVKA-II is not detectable, but it is found relatively frequently in breast­
fed infants without vitamin К prophylaxis at birth (10). Although biochemical 
markers of vitamin К deficiency are only of limited value in assessing clinical rel­
evance, they provide a most sensitive way to determine which group of infants is at 
risk for HDN. 
43 SUBJECTS AND METHODS 
Subjects 
A total of 331 infants, bom spontaneously vaginally at the University Hospital of 
Nijmegen or at home under midwife guidance, were enrolled. Inclusion criteria 
were; a gestational age of 37 wks or more, a birth weight over the 2.3rd centile, and 
an Apgar score of 7 or more at 5 min. The mother had to be healthy and not be 
taking vitamin K, anticoagulants, antibiotics or anti-epileptics. All mothers intended 
to breast-feed their child. After the parents had given informed consent, the 
neonates received vitamin К prophylaxis on the first or second day of life. The new­
borns were randomly allocated to one of the two treatment groups. One group 
(n = 165) received 1 mg vitamin Kj orally (1 mg/ml Phytomenadione, Konakion^, 
Hoffmann-La Roche). The other group (л = 166) received 1 mg vitamin K; i.m. 
(Konakion 2 mg/ml). Some characteristics of the infants are represented in Table 
4.1. No item was significantly different between the groups at start, nor at other 
moments of study (χ2 and Student / test). 
If the child was still exclusively breast-fed, blood was sampled at the age of 2 weeks 
and 1 and 3 months. In other words, when the mother stopped nursing follow-up 
was terminated. A sample of 5 ml of blood was drawn by venepuncture: 2 ml of 
citrated blood (in silicone coated tubes containing 10% (v/v) of sodium citrate 3.8%) 
and 3 ml of coagulated blood with no additive. After measuring blood coagulability 
by Thrombotest (TT) (Nijegaard & Co, Oslo, Norway), the citrated blood was 
centrifuged (5000rpm for 10 min) and the removed plasma stored at -70oC until 
coagulation parameters were determined. The coagulated blood was protected from 
daylight immediately after sampling, centrifuged (ЗОООгрт for 5 min) and the serum 
stored at -20oC for vitamin Ky determination. Samples from one child were assayed 
in one run. All samples were coded to provide blind analysis. 
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Table 4.1 Comparison of the two study-groups of healthy breast-fed infants (mean ± 
SD) 
Number of infants 
Sex (% male) 
Gestational age (wk) 
Birth weight (g) 
Apgar score at 5 min 
Arterial cord blood pH 
Age at vit К administr (h) 
Follow-up assessments: 
Age at 1st venepuncture (days) 
Age at 2nd venepuncture (days) 
Age at 3rd venepuncture (days) 
Oral 
165 
55.8 
39.8 
3424 
9.7 
7.26 
19.9 
14.1 
30.5 
88.6 
group 
± 
± 
± 
± 
± 
± 
± 
+ 
1.3 
439 
0.5 
0.07 
12.7 
1.2 
1.8 
5.6 
Intramuscular group 
166 
47.0 
40.1 ± 
3417 ± 
9.7 ± 
7.26 ± 
13.6 ± 
14.0 ± 
30.5 ± 
89.5 ± 
1.2 
440 
0.6 
0.07 
13.5 
1.3 
1.8 
5.6 
Laboratory determinations 
Activities of clotting factors VII and X were measured by chromogenic substrate 
assays, with substrate S2765 (Coa-set FVII kit, Kabi Diagnostica, Mölndal, Sweden) 
and substrate S2337 (Coatest FX kit, Kabi), respectively. These methods are not 
sensitive to PIVKA factors. 
PIVKA-H was assayed by an enzyme-linked immunosorbent assay, using a mono-
clonal antibody previously described (Eitest mono P-II, Eisai, Tokyo, Japan) (11). 
This antibody quantitatively reacts with descarboxylated prothrombin (PIVKA-II) 
and does not cross react with native prothrombin. PIVKA-II concentrations are ex-
pressed in arbitrary units (AU)/ml, so that 1 AU corresponds with 1 /ig of purified 
prothrombin. In severe vitamin К deficiency PIVKA-II can amount to more than 20 
AU/ml. The detection limit of 0.10 AU/ml was used as the upper normal limit, 
defining PIVKA-II concentrations higher or lower than that value as PIVKA-II 
positive or negative, respectively. 
Vitamin Kj was extracted from 1 ml serum samples by a two-step high performance 
liquid chromatographic (HPLC) procedure, according to the method of Lambert et 
al. (12, 13). A few modifications were applied. The assays were performed with two 
Spectra Physics SP8800 systems (Spectra Physics, Santa Clara, USA) equipped with 
Rheodyne 7125 manual injectors (Rheodyne, Cotati, USA), with 100 μ\ sample 
loops. Vitamin Щпз) w a s u s e d a s a n internal standard. The first HPLC step was 
used for preseparation of vitamin Kj and K ^ j i on a microspher-Si column 
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(Chrompack, Middelburg, Netherlands). Locations of vitamin K^ and internal 
standard were detected with a variable wavelength detector model 770 (Spectra 
Physics) set at 248 nm. Final separation and quantification were performed during 
the second HPLC step, using a microspher-C18 column (Chrompack) and post-
column chemical reduction with tetramethylammonium-octahydridotriborate for fluor-
escence detection (X£r=325nm, х
е ш
=450пт) with a Waters 470 fluorescence 
detector (Waters, Millipore Corp., Milford, USA). Concentrations were calculated 
from relative peak heights of vitamin K; versus known amount of internal standard. 
Recovery of vitamin K i from standard solutions added to normal serum was 85 ± 
5%, with a detection limit of 45 pg/ml. 
In all PIVKA-II positive samples and in about 30% of other samples Alanine 
aminotransferase (ALAT) was determined (normal <40 U/l). 
Statistical analyses 
x
2
, Student t, Mann-Whitney U, and Wilcoxon's one-sample tests and Spearman's 
rank correlation coefficient were used where appropriate. 
The study was approved by the local medical ethical committee. 
4.4 RESULTS 
None of the infants had clinical symptoms of bleeding diathesis or severely disturbed 
coagulation parameters. 
The decrease in number of infants studied during follow-up is caused by frequent 
stopping of exclusive breast-feeding before the age of three months. Some values 
are missing due to sampling errors. The number of samples studied is stated where 
different. 
Results of coagulation tests are shown in Fig. 4.1. TT and activities of clotting factors 
VII and X revealed no difference between the two groups at any of the ages (M-W, 
p>0.05). As to be expected, a rise in activity between 14 and 30 days of age was 
found for these coagulation parameters (Wilcoxon, p<0.01). 
Results of PIVKA-II determination are represented in Table 4.2. Two weeks after 
birth PIVKA-II could not be demonstrated in any of the 285 infants studied. At 1 
month PIVKA-II was detectable in 4 out of 262 infants; 1 in the i.m. group (0.8%) 
and 3 in the oral group (2.2%). PIVKA-II concentrations ranged from 0.10 to 0.47 
AU/ml (see Table 4.3). The difference in percentages of positive samples after oral 
compared with i.m. administration is not statistically significant (χ2, p=0.34). The 
95% confidence limits of the difference were -1.5 to 4.3%. At the age of 3 months 
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Oral У//Л Intramuscular I I SD 
Activity (%) 
120 η . . 
2 weeks 1 month 3 months 
AGE 
Fig. 4.1 Median (SD) of Thrombotest (TT) values and activities of clotting factors VII 
and X in breast-fed infants at the age of 2 weeks and 1 and 3 months after either oral 
or i.m. vitamin К prophylaxis at birth. Values are expressed as a percentage of normal 
adult pooled plasma. 
Table 4.2 Presence of PIVKA-II (> 0.10 AU/ml) in breast-fed infants of 
different ages after either oral or i.m. vitamin К prophylaxis at birth (n). 
Oral group 
Intramuscular group 
2 weeks 
0 (145) 
0 (140) 
TIME AFl'HR BIRTH 
1 month 
3 (135) 
1 (127) 
3 months 
7 (68) 
8 (63) 
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PIVKA-II could be detected in 15 out of 131 infants; 7 in the oral group (10.3%) 
and 8 in the i.m. group (12.7%). The 95% confidence interval of the difference 
between the oral and i.m. group was -13.3 to 8.5% (p=0.67). PIVKA-II concentra­
tions ranged from 0.10 to 0.32 AU/ml 
Vitamin K] plasma concentrations decreased significantly during follow-up in both 
groups (Wilcoxon, p<0.001), see Fig. 4.2. At the age of 2 weeks the mean ± SD of 
1608 ± 873 pg/ml in the i.m. group (n=64) was significantly higher than that of 815 
± 414 pg/ml in the oral group (n=74) (M-W, p<0.0001). At the age of 1 month the 
level was still significantly higher in the former group: 615 ± 272 pg/ml (л=84) ν 
391 ± 207 pg/ml (n=94); p<0.0001. Remarkably, at 3 months concentrations were 
still slightly different: 329 ± 186 pg/ml (n=57) ν 268 ± 174 pg/ml (n=62); p=0.03. 
Plasma concentrations of vitamin K^ did not correlate with sex, gestational age, birth 
weight, Apgar score, or arterial cord blood pH, nor with Thrombotest, activities of 
factors VII or X, or PIVKA-II concentration. 
Vitamin K1 (pg/ml) 
2 w e e k s 1 month 3 months 
AGE 
Fig. 4.2 Vitamin Kj plasma concentrations in breast-fed infants at 2 weeks and 1 and 
3 months of age after either oral or i.m. vitamin К prophylaxis at birth. 
In Table 4.3 individual results of PIVKA-II, Thrombotest, factors VII and X, vitamin 
Kj, and ALAT determinations are shown for the infants positive for PIVKA-II. 
Values for TT and factors VII and X were not different from infants negative for 
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PIVKA-II. Similarly, vitamin Ky concentrations were not extremely low. At the agee 
of 3 months mean ± SD vitamin K^  concentration in the infants positive for 
PIVKA-II was 221 ± 74 pg/ml, compared with 312 ± 191 pg/ml in the infants 
negative for PIVKA-II (M-W, p=0.16). Results of ALAT determinations indicate 
that liver dysfunction is not a major cause for the appearance of PIVKA-II. No 
relevant correlations between the concentration of PIVKA-II and other parameters 
could be detected. 
Table 4.3 Results of PIVKA-II, Thrombotest, clotting factors VII and X, vitamin Kj 
and ALAT in the PIVKA-II positive infants. 
Group Age PIVKA-II ТТ" F VII* F Xa 
(mo) (AU/ml) (%) (%) (%) 
Vit К, ALAI* 
(pg/ml) ( Щ ) 
Oral 
Oral 
Oral 
I.m. 
I.m. 
I.m. 
I.m. 
Oral 
Oral 
I.m. 
I.m. 
I.m. 
Oral 
Oral 
I.m. 
I.m. 
Oral 
Oral 
Oral 
1 
1 
1 
1 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
0.47 
0.16 
0.12 
0.10 
0.32 
0.31 
0.29 
0.28 
0.22 
0.19 
0.14 
0.14 
0.13 
0.12 
0.11 
0.11 
0.11 
0.10 
0.10 
90 
70* 
>100 
>100 
>100 
100 
>100 
>100 
>100 
>100 
65* 
>100 
70* 
57* 
>100 
>100 
>100 
>100 
-
44 
77 
60 
74 
99 
85 
61 
70 
66 
95 
78 
62 
74 
66 
89 
72 
89 
67 
64 
57 
47 
43 
51 
52 
61 
52 
47 
51 
74 
48 
54 
48 
49 
43 
67 
46 
63 
37 
m
c 
189 
243 
436 
190 
220 
238 
140 
125 
328 
357 
235 
126 
263 
242 
— 
184 
357 
-
21 
15 
6 
23 
20 
58 
31 
16 
13 
17 
26 
8 
20 
12 
44 
16 
11 
18 
19 
a
, IT (Thrombotest) and factors VII and X are expressed as a percentage of normal adult pooled 
plasma. 
b
, ALAT (Alanine aminotransferase), normal value < 40 U/l. 
c
> -- missing value due to insufficient volume of serum. 
*, activity less than mean - 2 SD of PIVKA-II negative infants of that age. 
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4.5 DISCUSSION 
Concentrations of vitamin Kj in blood vary widely, according to the diet of the 
person and the determination method used. The reference interval reported for 
fasting adults, measured by a technique comparable with ours, ranges from 62 to 
980 pg/ml (14). The reference interval for neonates and infants is still unknown. 
Mean plasma concentrations in healthy breast-fed infants of 1 month of age without 
vitamin К prophylaxis are reported to be 500 - 700 pg/ml (10, 15). Formula-fed 
infants have much higher concentrations of 3000 - 4500 pg/ml, because of the 
relatively high concentration of vitamin K; in formula (60 μg/l) compared with 
human milk (2 g^/1) (10, 15). Me Ninch et al. (4) reported vitamin K; plasma 
concentrations in breast-fed infants after 1 mg vitamin K^ orally or i.m. at birth. In 
the oral group the peak median concentration occurred earlier, but was lower. In 
both groups vitamin K; concentrations declined rapidly, after 24 hours the mean 
was 23 ng/ml in the oral group and 444 ng/ml in the i.m. group. The present study 
demonstrates that after 2 weeks the vitamin Kj concentrations are still raised; 
concentrations of about 1600 pg/ml after i.m. injection and of 800 pg/ml after oral 
administration were found. At the age of 1 month concentrations were declined to 
about 600 and 400 pg/ml, respectively. Other reports confirm that 4 to 6 weeks after 
an i.m. injection of 1 mg vitamin K ,^ plasma levels are back at unsupplemented 
values (10, 16). Nevertheless, at all ages vitamin K^ concentrations were in the oral 
group. To our knowledge, vitamin Ky concentrations beyond the first week of life 
after a single oral prophylaxis were not reported before. To determine whether the 
lower vitamin Ky plasma concentration after oral application also entails a worse 
protection against vitamin К deficiency, we have to compare coagulation parameters. 
TT and activities of clotting factors VII and X revealed no difference between the 
two groups. However, these coagulation tests are not sensitive enough to detect bio­
chemical vitamin К deficiency (17). Accordingly, ТГ and factors VII and X were not 
different between infants positive and negative for PIVKA-II. In contrast to vitamin 
Ky plasma concentrations and activities of clotting factors, PIVKA-II detection is a 
more direct reflection of vitamin K-dependent carboxylation of clotting factors in the 
liver. As mentioned previously, detection of PIVKA-II has no clinical consequences, 
but it does indicate whether enough vitamin К has been available to carboxylate all 
vitamin K-dependent proteins. Prolongation of low vitamin К intake may lead to 
serious complications. 
In cord blood, using the same method as we did, Motohara et al. (18) detected 
PIVKA-II in 21.5% of 102 samples. At the age of 3 to 5 days 50 to 60% of infants 
were PIVKA-II positive if they were breast-fed and had not received vitamin К 
prophylaxis at birth (18). At the age of 1 month still 12.3% were positive (19). So, 
biochemical vitamin К deficiency occurs rather frequently in unsupplemented breast-
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fed infants. Widdershoven et al. (10) compared PIVKA-II concentrations in breast­
fed and formula-fed infants. At the age of 4 days about 10% of both groups had 
РГ КА-ІІ in their blood. At 1 month of age PIVKA-II was not detected in any 
formula-fed infant, compared with in 5.5% of breast-fed infants. At 3 months of age 
no formula-fed infant was positive, compared with 7.5% of breast-fed infants. Thus, 
formula-feeding seems an effective way to prevent the appearance of PIVKA-II in 
the blood of young infants, probably due to the high intake of vitamin Kj. PIVKA-II 
was not detectable in any of our infants of 2 weeks old. This corresponds with the 
still raised vitamin K; concentrations in both groups. Surprisingly, in 4 one-month-
old infants PIVKA-II was detected. However, the concentration in the only positive 
infant of the i.m. group was at the limit of detection. So, in the i.m. group hardly 
any one-month-old infant had PIVKA-II detectable, while a few in the oral group 
had. Exact comparison of our PIVKA-II results with those of Motohara et al. (19) 
and Widdershoven et al. (10) is hampered by the fact that our method is more 
sensitive. Their detection limit amounted to 0.13 compared with 0.10 AU/ml in our 
study. If we applied their detection limit as a selection criterium just 2 one-month-
old infants would remain positive, thus strenghtening the clinically relevant dif­
ference in PIVKA-II detectability between our supplemented and their unsupple-
mented one-month-old breast-fed infants (χ2, p<0.01). Even without correction, 
PIVKA-II was less frequently detected in our i.m. group than in the unsupple-
mented infants of Widdershoven et al. (10), (1/127 ν 4/73, p<0.05). Our oral group 
did not differ significantly from the unsupplemented infants of Widdershoven et al. 
(3/135 ν 4/73, p=0.21). This demonstrates that i.m. vitamin К seems still effective at 
the age of 1 month, while oral vitamin К is not. 
Surprisingly, at the age of 3 months a rather high percentage of children in both the 
oral and i.m. groups had PIVKA-II detectable, indicating that neither prophylaxes 
was completely effective by that age. Vitamin Kj concentrations were declined to 
values of 300 pg/ml. Although vitamin K; concentrations in the i.m. group were 
slightly higher than in the oral group, both levels seem insufficient to prevent 
biochemical symptoms of vitamin К deficiency in all infants. Other reports confirm 
the reappearance of PIVKA-II after a single vitamin К administration at birth. 
Motohara et al. (18) reported a decrease in PIVKA-II detectability on the third and 
fifth day of life after a single oral dose of 5 mg vitamine K2 at birth. At the age of 
1 month, however, no significant reduction in PIVKA-II detectability was demon­
strated unless a second oral dose was administered at the age of 14 days (19). 
Widdershoven et al. (10) detected PIVKA-II in none of 48 one-month-old infants, in 
1 of 29 two-month-old infants, and in 1 of 23 three-month-old infants after the 
administration of 1 mg vitamin Kj i.m. at birth. 
We failed to detect an association between PIVKA-II and vitamin K^ plasma con­
centrations. Vitamin K; concentrations were not different in children positive for 
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PIVKA-II compared with infants negative for PIVKA-II. This may be caused by the 
fact that PIVKA-II has a half-life of about 70 hours and hence can still be present 
in plasma when the vitamin К deficiency has been corrected (9). Moreover, due to 
frequent feedings, plasma concentrations of vitamin Kf in infants vary widely. The 
plasma half-life of tritiated vitamin K; has been reported to be 120-150 min (20). 
Information about hepatic vitamin К stores in infants is limited. Shearer et al. (21) 
reported that in unsupplemented term neonates hepatic vitamin K^ concentrations 
were no more than about 1 ng/g liver (fresh weight). Total liver stores amounted to 
0.1 μg. In adults a much higher mean concentration of 5.5 ng/g was measured, 
resulting in total stores of 8 /tg. When the newborn had been given an i.m. injection 
of vitamin K^ (0.5-1.0 mg) endogenous hepatic values remained raised for at least 
one week. Besides vitamin K; different forms of vitamin K2 (menaquinones 6 to 12) 
can be detected in the liver (21). In adults menaquinones even accounted for some 
75-97% of total hepatic stores of vitamin К on a molar basis. In the neonate, how­
ever, menaquinones were not detectable until about 14 days post-partum. Thereafter 
a gradual build-up was indicated and adult concentrations were attained about one 
month after birth (21). However, the extent of vitamin K2 utilisation remains 
controversial. Nevertheless, besides vitamin K^ vitamin K2 has to be considered 
when assessing vitamin К status. Altogether, the plasma vitamin Kj concentration 
may not adequately represent the total amount of vitamin К that is available as a 
cofactor for the carboxylase enzyme in the liver. 
Wallin (22) has reported evidence to maturation of the vitamin K-dependent 
carboxylation system in fetal-neonatal rats. At the age of 7 days adult values of 
carboxylase activity were reached. But activities of the two pathways that provide 
carboxylase with reduced vitamin KH^ cofactor (vitamin-K-epoxide reductase and 
vitamin К reductase) were never as high as in adult liver. In other words, it might 
be possible that an increased requirement of vitamin К exists in early infancy, due 
to immature re-utilisation of vitamin-K-epoxide. Again, the vitamin Ky reference 
interval for fasting adults cannot automatically be applied to (non-fasting) young 
infants. Moreover, individual difference in enzyme maturation and therefore 
individual difference in vitamin К requirement could exist. 
To summarise, single oral or i.m. administration of 1 mg vitamin K^  postnatally may 
not offer complete protection against late biochemical vitamin К deficiency. 
Correspondingly, except for one infant with classical HDN (23), most case reports of 
failures of vitamin К prophylaxis concern late HDN (1, 24). Epidemiologically, i.m. 
vitamin К prophylaxis appears to have a lower incidence of failure (6-8). In a recent 
survey in the British Isles, 27 cases of HDN were recorded (8). Seven of them 
occurred in spite of oral vitamin К prophylaxis at birth. No failures were recorded 
after i.m. administration, although there was uncertainty about i.m. vitamin К in one 
case. The relative risk for babies who had received oral vitamin К compared with 
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babies who had received i.m. vitamin К was 13:1. The relative risk without prophy­
laxis was 81:1 (8). A schedule of repeated oral doses was considered (25). Taking 
our results as well as epidemiological evidence into account, we suggest that for 
complete protection of breast-fed infants against late HDN, vitamin К administration 
should be repeated. Whether a monthly, weekly, or daily administered oral dose 
should be recommended, deserves further investigation. 
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5.1 ABSTRACT. 
Vitamin К prophylaxis has been developed to prevent classic haemorrhagic disease 
of the newborn (HDN). Single vitamin К administration after birth has been re­
ported to fail, resulting in late HDN. The preventive effect of an oral administration 
of 1 mg vitamin K; repeated weekly during the first three months of life, was 
studied in 48 healthy breast-fed infants by determination of Thrombotest (IT), 
PIVKA-II and vitamin K; concentrations at the age of 4, 8 and 12 weeks. All 
infants showed normal TT values and PIVKA-II was not detectable. Vitamin K; 
concentrations were negatively correlated with the number of days elapsed since the 
most recent vitamin К administration. Six to seven days after the latest application 
mean levels were 1223, 927 and 748 pg/ml at the age of 4, 8 and 12 weeks, respect­
ively. In conclusion, weekly administration of 1 mg vitamin K; offers complete 
protection against vitamin К deficiency and does not result in an accumulation of 
vitamin Kj in the blood. 
5.2 INTRODUCTION 
Vitamin К deficiency can cause haemorrhagic disease of the newborn (HDN), of 
which three patterns have been differentiated: early HDN within 24 hours after 
birth, classic HDN in the first week of life and late HDN after the first week (1, 2). 
These haemorrhages may be fatal or may cause severe morbidity. Breast-feeding 
plays an important role in the pathogenesis of classic and late HDN (2). 
Vitamin К prophylaxis was introduced to prevent classic HDN and its efficacy has 
been established beyond any doubt (3, 4). At the moment many countries recom­
mend vitamin К prophylaxis after birth, but it is still controversial whether this also 
protects infants against late HDN (2). Clinical experience suggests that parenteral 
vitamin К prophylaxis at birth offers some protection against late HDN, since most 
case-reports concern breast-fed children who had not received vitamin К postnatally 
(2). Nevertheless, more than 100 cases of late HDN despite either oral or intra­
muscular vitamin К prophylaxis at birth, have been reported worldwide (5, 6, other 
references on request). Intracranial haemorrhage accounted for at least half of the 
bleeding episodes and the mortality rate was over 30%. In accordance with these 
case-reports, we demonstrated that a single administration of vitamin Kj after birth 
did not completely prevent biochemical signs of vitamin К deficiency in breast-fed 
infants beyond the age of one month (7). 
Vitamin К acts as a cofactor for the vitamin K-dependent carboxylase enzyme, 
which is involved in the production of coagulation factors II, VII, IX and X, and 
proteins С and S. The carboxylation of specific glutamic acid residues to γ-car-
boxyglutamic acid residues confers unique calcium binding properties upon these 
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proteins which are essential for an effective haemostatic function. When vitamin К 
is lacking, descarboxylated proteins which are not functional appear in the blood. 
These are known as proteins induced by vitamin К absence (PIVKA). The deter­
mination of PIVKA-II (descarboxylated prothrombin) is a sensitive way of establish­
ing biochemical vitamin К deficiency (8). The detection of PIVKA-II in a single 
patient may not be associated with bleeding symptoms, but the assay is of value in 
defining groups of infants risking vitamin К deficiency. 
In this chapter the results are reported of a study of 48 healthy breast-fed infants 
who received a weekly oral dose of 1 mg vitamin Ky during the first three months 
of their lives. To determine the efficacy in the prevention of late vitamin К 
deficiency Thrombotest, PIVKA-II and vitamin Ky concentrations were measured 
monthly. The results were compared with previous results of infants who had 
received a single oral or intramuscular vitamin К administration at birth (7). 
S3 SUBJECTS AND METHODS 
This study was approved by the local medical ethical committee and all parents 
signed a written informed consent. 
Forty-eight infants, born vaginally and spontaneously at the University Hospital 
Nijmegen or at home under midwife guidance, were recruited. Inclusion-criteria 
were as previously reported (7); a gestational age of 37 weeks or more, a birth 
weight over the 2.3rd percentile and an Apgar score of 7 or more at 5 minutes. 
Arterial cord blood pH was measured in 25 neonates and ranged from 7.13 to 7.39. 
Some characteristics of these infants, as well as of our previously reported infants 
without weekly supplements (controls), are shown in Table 5.1. None of the para­
meters differed statistically between the groups. The mothers were healthy as well 
and did not use vitamin K, anti-coagulants, antibiotics or anti-epileptics. They 
intended to breast-feed their child for at least three months. 
After the parents had given informed consent, the infants received 1 mg vitamin Ky 
orally (20 mg/ml Phytomenadione, Konakion^, Hoffmann-La Roche) on the first or 
second day of life. This administration was repeated weekly by the parents just prior 
to a feeding. When the solution was spat out the administration was repeated. Date 
and time of administration were recorded. 
If the child was still exclusively breast-fed, blood was sampled at the age of 4, 8 and 
12 weeks, if possible just before the next vitamin К administration. The mean ages 
at assessments were 29 ± 2.5, 57 ± 1.6 and 85 ± 2.6 days. Five ml of blood were 
drawn by venepuncture: 2 ml of citrated blood (in silicone-coated tubes containing 
10% (v/v) of sodium citrate 3.8%) and 3 ml of coagulated blood with no additive. 
After measuring a Thrombotest (Reagents, Nijegaard & Co, Oslo, Norway) the 
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citrated blood was centrífuged (350Cb¡g for 10 min) and the removed plasma was 
stored at -IQPC until PIVKA-II assay. The coagulated blood was screened from the 
light immediately after sampling, centrífuged (lOOOxg for 5 min), and the serum was 
stored at -IQfC for vitamin Ky determination. Samples from one child were assayed 
in one run. 
Table 5.1. Characteristics of study and control breast-fed infants. 
Number 
Male (%) 
Gestational age (wk) 
Birth weight (g) 
Apgar score at 5 min 
Arterial cord blood PH 
Study 
48 
46 
39.8 ± 1.5 
3381 ± 450 
9.5 ± 0.8 
7.25 ± 0.06 
Control 
331 
51 
39.9 ± 1.3 
3420 ± 439 
9.7 ± 0.6 
7.26 ± 0.07 
PIVKA-II concentrations were determined by an enzyme-linked immunosorbent assay 
previously described, using a monoclonal antibody (Eitest mono P-II, Eisai, Tokyo, 
Japan) (9). This antibody quantitatively reacts with descarboxylated prothrombin 
(PIVKA-II) and does not cross react with native prothrombin. PIVKA-II levels are 
expressed in arbitrary units (AU) per ml, so that 1 AU corresponds with 1 /ig of 
purified prothrombin. In case of severe vitamin К deficiency PIVKA-II can rise to 
more than 20 AU/ml. The detection limit was 0.10 AU/ml. 
Vitamin Kj was determined by a two-step high performance liquid chromatographic 
(HPLC) procedure, according to the method of Lambert et al. (10, 11). Few 
modifications were applied, as stated elsewhere (7). The detection limit was 45 
pg/ml. 
For statistical evaluation Student / test was applied on infants' characteristics; 
Fisher's exact test on PIVKA-II results; Wilcoxon's one and two sample tests on 
vitamin Kj concentrations. Spearman's rank correlation coefficient was used for 
correlation detection. 
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5.4 RESULTS 
All infants remained healthy during follow-up. No side-effects of vitamin К treat­
ment were reported. None of the infants showed a bleeding diathesis. 
The lowest Thrombotest value measured was 55%. At all ages median Thrombotest 
values were 100%. 
PIVKA-II concentrations were measured in 42, 41 and 43 infants at the age of 4, 8 
and 12 weeks, respectively. No PIVKA-II was detected in any sample. Comparison 
with the control group revealed a statistically significant difference at the age of 12 
weeks (Table 5.2). In fifteen breast-fed infants without weekly supplements PIVKA-
II was detectable at the age of 12 weeks; in 7 out of 68 infants after oral and in 8 
out of 63 after intramuscular administration of vitamin K; at birth (7). 
Vitamin Kj plasma concentrations depended on the number of days elapsed since 
the latest vitamin Kj administration (r=-0.50, p=0.000, n = 115). Even after consider­
ing this time dependency, concentrations varied widely, see Fig. 5.1. Samples 
obtained 6 to 7 days after the latest vitamin К administration showed mean values 
of 1223 ± 647 (n=22), 927 ± 504 (n=32) and 748 ± 352 pg/ml (n=27) at the age 
of 4, 8 and 12 weeks, respectively. The lowest level found was 278 pg/ml. Vitamin 
Kj concentrations at the age of 4 weeks were significantly higher than at 8 and 12 
weeks (p<0.05). Values at 8 and 12 weeks did not differ significantly from each 
other. There were definitely no indications of an accumulation of vitamin K^ in the 
blood due to the repeated doses. 
In the study group vitamin Kj concentrations were significantly higher than in the 
control group. For the control group there are no data available at the age of 8 
weeks; the mean levels at 4 and 12 weeks are shown in Table 5.2. 
Table 5.2. Number of samples with PIVKA-II > 0.10 AU/ml, and vitamin Kj con­
centrations (mean ± SD) at the age of 4 and 12 weeks in weekly supplemented1 and 
control breast-fed infants (n). 
AGE (wk) 
Study group 
Control group 
PIVKA-II 
4 
0 (42) 
4 (262) 
0 
15 
12 
(43) 
(131)* 
Vitamin K, 
4 12 
1??3 + 647 (22) 748 + 352 (27) 
497 ± 264 (178)# 297 ± 182 (119)# 
, Samples obtained 6 to 7 days after the latest administration. 
', Study ν control group: Fisher's exact test, p<0.05. 
*, Study ν control group: Mann-Whitney test, p<0.001. 
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Fig. 5.1 Vitamin K1 plasma concentrations at the age of 4, 8 and 12 weeks in relation 
to the number of days elapsed since the latest vitamin К administration, in 48 infants 
receiving an oral dose of 1 mg vitamin K1 weekly. 
5.5 DISCUSSION 
In one-month-old unsupplemented healthy breast-fed infants mean vitamin K; 
plasma concentrations are reported to be 150 to 700 pg/ml (12-14). Formula-fed 
infants have much higher levels of 3000 to 6000 pg/ml (12-14). When a single oral 
dose of vitamin K; was administered at birth, after 2 weeks concentrations were 
about 800 pg/ml. From then the concentrations declined rapidly to unsupplemented 
levels (7). After an intramuscular injection concentrations at the age of 2 weeks 
were higher than compared with an oral dose (1600 pg/ml), but these concentrations 
also quickly declined to unsupplemented levels (7). In other words, a single ad­
ministration of vitamin Kj at birth has a limited effect on vitamin Kj plasma con-
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centrations beyond the neonatal period. Weekly repetition of the administration 
prevented the plasma concentration from diminishing to unsupplemented levels. 
Mean concentrations at the age of 4, 8 and 12 weeks - obtained just before the next 
administration - were about 1200, 900 and 750 pg/ml. 
Despite a rather huge administration of vitamin K;, plasma concentrations were 
moderate and still much lower than in formula-fed infants. This again illustrates the 
rapid disappearance of vitamin K, from the circulation. Tritiated vitamin Kj was 
reported to have a plasma half-life of 120-150 min (15). Bottle-fed infants continual-
ly receive a small extra dose of vitamin K;, thus the plasma level remains at a high 
level. The prescribed minimum concentration for formula is 26 pg/l vitamin K; (16), 
but they usually contain about 50 /jg/l. The daily intake of formula-fed infants was 
reported to be about 50 ^g vitamin Kj (14). Unsupplemented breast-fed infants 
daily ingest less than 1 ^g vitamin Kj (14), while the recommended daily intake 
(RDI) amounts to 5 ¡ig (16). Accordingly, in formula-fed infants PIVKA-II is not 
detectable (8) and haemorrhagic disease is almost confined to breast-fed infants (2). 
Prothrombin times were reported to be longer in three-month-old breast-fed infants 
than in formula-fed infants, even despite vitamin К prophylaxis at birth (14). 
Administration of 1 mg vitamin Kj per week corresponds to approximately 150 /ig 
per day. This is considerably more than the RDI and lower doses for supplement­
ation might be equally effective. 
Unfortunately, hepatic vitamin K¡ concentrations are unknown. However, as no 
PIVKA-II was detectable, a sufficient store of vitamin К must have been available 
for the carboxylation of prothrombin. As stated before, PIVKA-II was detected 
rather frequently in infants who had only received vitamin K^  at birth (7). Thus, 
weekly oral administration of vitamin K; prevented the appearance of signs of 
vitamin К deficiency. This is in agreement with results of other groups. Motohara et 
al. (17) reported a decrease in PIVKA-II detectability on the third and fifth day of 
life following a single oral dose of 5 mg vitamin K2 at birth. At the age of one 
month, however, no significant reduction in PIVKA-II detectability was demonstrated 
unless a second oral dose was administered at the age of 14 days (18). 
To our knowledge this is the first report of vitamin K^ and PIVKA-II blood levels 
determined in infants receiving weekly vitamin К supplementation. This regimen 
turned out to be reliable for the prevention of vitamin К deficiency in breast-fed 
infants. Current Dutch recommendations on vitamin К prophylaxis include oral or 
intramuscular vitamin K; administration (1 mg) at birth for all neonates, followed by 
weekly (1 mg) or daily (0.025 mg) supplementation of vitamin K; during a period of 
three months for breast-fed infants (19). The effect of daily administration is still to 
be evaluated. A special feature of these recommendations is that the administration 
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of vitamin К is performed by the parents. Since they want the best for their child, 
compliance is good. 
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6.1 ABSTRACT 
Vitamin К prophylaxis is recommended to prevent the hazard of haemorrhage 
caused by vitamin К deficiency in young infants. A single administration after birth 
seems inadequate to completely prevent late haemorrhagic disease in breast-fed in­
fants. The preventive effect of a daily oral dose of 25 μg vitamin K;, which is 
comparable to about half the dose ingested by formula-fed infants, was evaluated in 
58 breast-fed infants. No clinical or biochemical signs of vitamin К deficiency 
occurred; PIVKA-II was not detectable and vitamin K; concentrations were 
moderately elevated. Vitamin K^ concentrations were negatively correlated with the 
number of hours elapsed since the latest gift. Twenty to 28 hours after the ad­
ministration mean concentrations (± SD) were 1972 (± 2028), 1371 (± 1139) and 
1068 (± 713) pg/ml at the age of 4, 8 and 12 weeks, respectively. Vitamin K; 
concentrations in formula-fed infants (л = 10) were around 7000 pg/ml. In conclusion, 
daily supplementation of 25 μg vitamin K; can be recommended for breast-fed 
infants to prevent vitamin К deficiency beyond the neonatal period. 
6.2 INTRODUCTION 
The term 'haemorrhagic disease of the newborn' (HDN) was first used in 1894 by 
Townsend to describe an acquired bleeding disorder in newborns (1). After the 
discovery of vitamin К in 1929, it was soon established that HDN was caused by a 
deficiency of vitamin К and that administration of vitamin К was effective in therapy 
and prevention of HDN. In 1961 the Committee on Nutrition of the American 
Academy of Pediatrics recommended to administer vitamin К prophylaxis to all 
newborn infants (2). Many countries adopted this recommendation, although 
controversies concerning the best dose, route and frequency of administration still 
exist. 
Several cases of HDN after the first week of life despite vitamin К prophylaxis at 
birth have been reported (3-6). This so called late HDN is frequently located 
intracranial and is often fatal (3). All victims appear to be breast-fed (3). In 
accordance with these case-reports, we demonstrated that a single administration of 
vitamin Kj after birth did not completely prevent laboratory evidence of vitamin К 
deficiency in breast-fed infants beyond the age of one month; in more than 10% of 
breast-fed infants proteins induced by vitamin К absence for factor II (PIVKA-II) 
were detectable in the blood at the age of 3 months (7). These proteins indicate 
that not all prothrombin was carboxylated completely due to a deficiency or an an­
tagonism of vitamin K. Determination of PIVKA-II is a sensitive way to establish 
biochemical vitamin К deficiency (8) and can be used to determine which group of 
infants is at risk for HDN. 
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Formula-fed infants have higher plasma levels of vitamin Kj than human milk-fed 
infants, and PIVKA-II is not detectable in their blood (9). Case-reports of late HDN 
in formula-fed infants are rare; of 198 infants with late HDN 3 were formula-fed 
(3). Therefore, to prevent symptoms of vitamin К deOciency in breast-fed infants, 
daily supplementation of an oral dose of vitamin Kj comparable to the amount 
ingested by formula-fed infants would be logical from a theoretical point of view. 
The effects of such a regimen, however, have never been studied. 
In the present study we evaluated the reliability of a daily administration of 25 /tg 
vitamin Kj in the prevention of vitamin К deficiency in healthy breast-fed infants. 
PIVKA-II and vitamin K; concentrations were measured monthly and were com­
pared with previous results of infants who received a single oral or intramuscular 
vitamin К administration at birth (7). In addition, plasma levels of vitamin K; were 
measured in 10 formula-fed infants. 
63 SUBJECTS AND METHODS 
The study was approved by the local medical ethical committee and all parents 
signed a written informed consent. 
Breast-fed infants 
Fifty-eight newborns who were born vaginally at the University Hospital Nijmegen 
or at home under midwife guidance, were enrolled. Inclusion-criteria were as 
reported previously (7); a gestational age 37 weeks or more, a birth weight over the 
2.3rd centile and an Apgar score 7 or more at 5 minutes. Arterial cord blood pH 
was measured in 37 neonates and ranged from 7.05 to 7.44. Some characteristics of 
these infants, as well as of our previously reported infants without daily supplemen­
tation (controls), are shown in Table 6.1. None of the parameters was statistically 
different between the groups. All 58 study newborns received routine vitamin К 
prophylaxis (1 mg) on the first day of life; 34 by oral route (20 mg/ml Phyto­
menadione, Konakion , Hoffmann-La Roche) and 24 by i.m. injection (2 mg/ml 
Konakion^). The mothers were healthy as well and did not take vitamin K, an­
ticoagulants, antibiotics or anti-epileptics. All mothers intended to breast-feed their 
child for at least 3 months. During this period of 3 months the parents administered 
daily 25 μg vitamin K; (4 drops 0.25 mg/g Konakion") to the infant, starting at the 
age of 1 week. Mean age at start was 7.5 days, range 6 to 11 days. When the 
solution was spat out, administration was repeated. 
If the child was still exclusively breast-fed, it was visited at home at the age of 4, 8 
and 12 weeks. Mean ages at assessments were 28 ± 1.8, 56 ± 3.0 and 83 ± 4.1 
days. Date and time of the two most recent vitamin К administrations were 
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recorded, as well as physical condition, medication and bleeding tendency of the 
baby. Five ml of blood were drawn by venepuncture: 2 ml of citrated blood (in 
silicone-coated tubes containing 10% (v/v) of sodium citrate 3.8%) and 3 ml of 
coagulated blood with no additive. The citrated blood was centrifuged (3500ед for 10 
min) and stored at -l(fC until PIVKA-II assay. The coagulated blood was screened 
from the daylight immediately after sampling, centrifuged (lOOQxg for 5 min) and 
stored at -20C,C for vitamin K^  determination. Samples from one child were assayed 
in one run. 
Table 6.1 Characteristics of study and control breast-fed infants. 
Number 
Sex (% male) 
Gestational age (wk) 
Birth weight (g) 
Apgar score at 5 min 
Arterial cord blood PH 
Oral vitamin К at birth (%) 
Study 
58 
48 
40.1 ± 1.2 
3487 ± 495 
9.6 ± 0.8 
7.28 ± 0.08 
59 
Control 
331 
51 
39.9 ± 1.3 
3420 ± 439 
9.7 ± 0.6 
7.26 ± 0.07 
50 
Formula-fed infants 
Ten formula-fed infants (5 males, 5 females) who were all fed on a formula 
containing at least 50 μg/l vitamin Щ (Nutrilon premium^, Nutricia, Zoetermeer, 
Netherlands), were studied for vitamin Kj plasma concentrations at the age of 4, 8 
and 12 weeks. The same inclusion criteria were applied as for the breast-fed infants. 
Mean ± SD gestational age was 40.1 ± 1 . 2 weeks, mean birth weight was 3229 ± 
466 gram and mean Apgar score at 5 min was 9.8 ± 0.4. Arterial cord blood pH 
was measured in 7 neonates and ranged from 7.07 to 7.40 (mean 7.25). These 
formula-fed infants also received a single dose of 1 mg (oral or intramuscular) 
vitamin Kj at birth. Blood sampling for vitamin K; determinations was performed at 
28 ± 1.9, 57 ± 2.5 and 85 ± 3.6 days of age. None of the characteristics mentioned 
was different for the formula-fed infants compared with the breast-fed infants 
(p>0.05). 
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Laboratory techniques 
PIVKA-II concentrations were determined by an enzyme-linked immunosorbent assay 
previously described, using a monoclonal antibody (Eitest mono P-II, Eisai, Tokyo, 
Japan) (10). This antibody quantitatively reacts with descarboxylated prothrombin 
(PIVKA-II) and does not cross react with native prothrombin. The detection limit 
was 0.10 AU/ml. 
Vitamin Kj was extracted from 1 ml serum samples and determined by a two-step 
HPLC procedure, according to the method of Lambert et al (11, 12). Few modifica­
tions were applied, as stated elsewhere (7). The detection limit was 45 pg/ml. 
Statistical analysis 
For statistical evaluation Student t test was applied on infants' characteristics, 
Fisher's exact test on PIVKA-II results, and Wilcoxon's one and two sample tests on 
vitamin K^  concentrations. Spearman's rank correlation coefficient was used for 
correlation detection. 
6.4 RESULTS 
All infants remained healthy during follow-up. No side-effects of vitamin К treat­
ment were reported in the breast-fed infants. None of the infants showed a bleeding 
tendency. 
PIVKA-II concentrations were measured in 48, 49 and 50 breast-fed infants of 4, 8 
and 12 weeks of age, respectively. No PIVKA-II was detected in any sample. 
Comparison with the control group revealed a statistically significant difference at 12 
weeks of age, Table 6.2. In fifteen breast-fed infants of the control group PIVKA-II 
was detectable at the age of 12 weeks; in 7 out of 68 infants who had received oral 
vitamin Kf at birth and in 8 out of 63 infants who had received intramuscular 
vitamin Kj at birth (7). The reduction in detection of PIVKA-II after daily ad­
ministration compared to single oral or intramuscular administration is statistically 
significant (0/50 ν 7/68, p=0.02; 0/50 ν 8/63, p<0.01). 
Mean vitamin K1 plasma concentrations in the 10 formula-fed infants were 7044 ± 
2954, 7885 ± 1716 and 6040 ± 2304 pg/ml at the age of 4, 8 and 12 weeks, 
respectively. The total range was 3028 to 10,884 pg/ml. The concentrations were 
significantly higher as compared with the breast-fed infants (p< 0.001). 
Vitamin K; concentrations in the breast-fed infants depended on the time elapsed 
since the latest vitamin Kj administration (r—0.59, p<0.001, и = 132). Even after 
correction for the number of hours elapsed since the most recent vitamin К supple-
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mentation, concentrations varied widely (Fig. 6.1). There was no correlation between 
the total number of days of vitamin К therapy and vitamin Щ plasma concentration 
(r=-0.10, p=0.14, n = 126). 
Samples obtained 20 to 28 hours after the latest vitamin К administration had mean 
values of 1972 ± 2028 (n=31), 1371 ± 1139 (n=32) and 1068 ± 713 pg/ml (n=33) 
at the age of 4, 8 and 12 weeks, respectively. Wilcoxon's one sample test applied on 
paired samples obtained 20 to 28 hours after the latest administration, revealed that 
the vitamin Щ concentrations at the age of 4 weeks were higher than at 8 weeks, 
although not statistically significant (p=0.06, η = 18 pairs). Levels at 4 weeks were 
significantly higher than at 12 weeks (p<0.01, n=21). Values at 8 and 12 weeks did 
not differ (p=0.33, n=20). 
Whether vitamin К prophylaxis at birth was given by oral route or by intramuscular 
injection was not a discriminating factor (p=0.28). 
Remarkably, one child had the lowest vitamin K^ plasma concentration at all three 
assessments; 163, 112, and 205 pg/ml, respectively. His mother insisted that the vit­
amin was administered correctly. PIVKA-II was not detectable and the Thrombotest 
amounted to >100% at all ages. 
Vitamin K^ concentrations in the study group were significantly higher than in the 
control group, Table 6.2. For the latter group there are no data available at the age 
of 8 weeks; the mean values at 4 and 12 weeks are shown in Table 6.2. 
Table 6.2 Number of samples with PIVKA-II > 0.10 AU/ml, and vitamin K¡ con-
centrations (mean ± SD) at the age of 4 and 12 weeks in daily supplemented1 and 
control breast-fed infants (n). 
AGE (wk) 
Study group 
Control group 
PIVKA-II 
4 
0 (48) 
4 (262) 
12 
0 (50) 
15 (131)* 
Vitamin K; 
4 12 
1972 ± 2028 (31) 1068 ± 713 (33) 
497 ± 264 (178)# 297 ± 182 (119)# 
1
, Samples obtained 20 to 28 hours after the latest administration. 
*, Study ν control group: Fisher's exact test, p=0.01. 
*, Study ν control group: Mann-Whitney test, p<0.001. 
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Fig. 6.1 Vitamin K} plasma concentrations at 4, 8 and 12 weeks of age in relation to 
the number of hours elapsed since the most recent vitamin К administration, in 48 
breast-fed infants who received a daily oral dose of 25 yg vitamin Kj. Leveb in 10 
formula-fed infants ranged from 3,000 to 11,000 pg/ml (data not presented). 
6.S DISCUSSION 
Neonates and young infants depend on their diet for vitamin К supply, since gut 
colonisation by vitamin K-producing bacteria has still to be established. Bacterial 
vitamin K2 was not detectable in neonatal liver until the age of about 2 weeks (13). 
Thereafter a gradual build-up was noticed, but it is unknown whether this is the 
result of absorption from the colon or of food contamination. 
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Recommended dietary intake (RDI) for infants up to 6 months is 5 Mg/day (14). 
Vitamin Kj content of human milk is relatively low; concentrations of about 2 /ig/l 
are reported (15). Conversely, the minimum vitamin Kj content of formula is 4 
/ig/100 kcal, corresponding to 26 pg/l (16). A maximum concentration is not 
established, but an upper limit of 100 ^g/1 is suggested (17). Most formulas contain 
at least 60 ¿ig/l vitamin Kj. Greer et al. (15) reported a vitamin Kj intake of about 
0.6 /ig/day by human-milk-fed infants and of 50 ng/day in formula-fed infants. As a 
consequence, a large difference in vitamin Ky intake exists between breast-fed and 
formula-fed infants and, more importantly, the RDI is not met by breast-feeding. 
The present suggested maintenance dose of 25 /ig/day increases the vitamin K^ 
intake of breast-fed infants significantly. An intake of 25 Mg/day is 5 fold as much as 
the RDI, but only half as much as the intake of formula-fed infants. 
Our mean vitamin K; level of about 7000 pg/ml in the formula-fed infants, confirms 
that vitamin Kj levels in formula-fed infants are much higher than in breast-fed 
infants. Mean levels reported for bottle-fed infants are 3000-6000 pg/ml, and for 
unsupplemented human-milk-fed infants 150-700 pg/ml (9,15,18). Consequently, 
formula-fed infants rarely develop symptoms of vitamin К deficiency; these are 
almost confined to breast-fed infants (3). Accordingly, prothrombin times were 
reported to be longer in three-month-old breast-fed infants than in formula-fed 
infants, even despite vitamin К prophylaxis at birth (15). This is in accordance with 
the fact that PIVKA-II was rather frequently detectable in three-month-old breast­
fed infants who had received a single dose of vitamin K^ at birth (7), while it was 
not detectable in supplemented infants. Repetitive administration seems necessary to 
completely prevent (biochemical evidence of) vitamin К deficiency in young infants. 
Daily supplements of 25 μg vitamin K; resulted in plasma vitamin K^ levels which 
were still significantly lower than those of formula-fed infants. As mentioned 
previously, formula-fed infants probably ingest twice as much vitamin K.¡. Moreover, 
they get their vitamin supplements in 5 to 6 portions per day, which may prevent 
decrease of the plasma concentration. The plasma half-life of tritiated vitamin K; 
was reported to be 120-150 min (19). 
Plasma concentrations of vitamin K; did not accumulate due to the repeated 
supplements. On the contrary, vitamin Kj levels declined during follow-up. Several 
explanations are conceivable. First, while the intake of vitamin K^ remains constant, 
liver weight and volume of distribution increase with age. Secondly, degradation of 
vitamin Kj may become more efficient. Nevertheless, the mean vitamin K^ concen-
tration of about 1000 pg/ml at the age of 12 weeks is still 3.5 times as high as the 
mean of the control group. 
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To our knowledge this is the first report of vitamin K; and PIVKA-II plasma con-
centrations determined in breast-fed infants receiving daily 25 pg vitamin K¡. This 
maintenance dose turned out to be effective in the prevention of biochemical evi-
dence of vitamin К deficiency, and therefore it will probably protect against late 
HDN. Because there is serious concern about a potential association of childhood 
cancer and intramuscular administration of 1 mg vitamin К at birth (20), a low 
maintenance dose might be preferable. 
Current Dutch recommendations on vitamin К prophylaxis include oral or i.m. 
vitamin K; (1 mg) at birth for all neonates, followed by weekly (1 mg) or daily 
(0.025 mg) administration of vitamin K^  during three months for breast-fed infant 
(21). A preparation of vitamin K; for daily application is currently available in the 
Netherlands (Davitamon К , Chefaro). We suggest to recommend daily administra­
tion of 25 ßg vitamin K; from one week until three months of age in breast-fed in-
fants as an alternative to weekly supplements. The limit of 3 months, however, is 
still arbitrary. Late HDN is rarely reported beyond this age (3). A low rate of 
exclusive breast-feeding at that age and introduction of solid food, which may 
account for additional vitamin К intake, might be responsible for this. Whether this 
low dose is also suitable to prevent vitamin К deficiency in sick children with 
cholestasis or patent hepatic disease can not be concluded from this study. 
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7.1 ABSTRACT 
Objective - The null hypothesis of this study is that the incidence of vitamin К 
deficiency in mother-infant pairs exposed to anticonvulsant drugs is not higher than 
in controls. 
Study design - Multicenter observational case-control study. 25 pregnant women on 
anticonvulsant therapy and 25 pregnant controls were studied for PIVKA-II and 
vitamin Kj concentrations at 32 weeks pregnancy and at delivery. 
Results - PIVKA-II was detectable in 54% of cord samples of the anticonvulsant 
group and in 20% of controls (χ2, p=0.01). In both groups vitamin K^  concentra­
tions in cord blood were predominantly below the detection limit. Maternal vitamin 
Kf concentrations were lower in epileptic women than in controls (Wilcoxon, 
p<0.05), but PIVKA-II was rarely present. 
Conclusions - The incidence of vitamin К deficiency is increased in neonates 
exposed to anticonvulsants prenatally. Their mothers, however, are rarely vitamin К 
deficient. 
7.2 INTRODUCTION 
Maternal anticonvulsant (AC) therapy during pregnancy can affect the fetus and 
cause neonatal complications. Haemorrhagic disease of the newborn (HDN) related 
to AC therapy was first reported in 1958 (1). Hitherto, at least 40 cases of neonatal 
bleedings associated with maternal AC therapy have been reported (2-4). The 
haemorrhagic diathesis is caused by depletion of vitamin K-dependent coagulation 
factors II, VII, IX and X. Onset of bleeding is usually within 24 hours after birth. 
Bleeding can occur at any site, but predominantly in the skin, the gastro-intestinal 
tract or the brain, and it is often fatal (4). 
In prospective studies the incidence of coagulation defects due to neonatal vitamin 
К deficiency was proved to be relatively high after intra-uterine exposure to AC 
drugs. Mountain et al. (5) reported abnormal coagulation tests in 50% of 16 fullterm 
neonates bom to mothers on AC therapy. Deblay et al. (6) found subnormal pro­
thrombin assays within 12 hours of birth in 27% of neonates born to women on AC 
medication. Seven percent suffered from severe bleedings. A more specific test for 
vitamin К deficiency is detection of proteins induced by vitamin К absence (PI-
VKA). Vitamin К is a cofactor necessary for posttranslational γ-carboxylation of 
glutamic acid residues in prothrombin and other vitamin K-dependent proteins, 
thereby providing these factors with effective calcium and phospholipid binding sites. 
In vitamin К deficiency, incompletely carboxylated proteins that are functionally 
defective appear in the circulation. These abnormal coagulation factors are called 
PIVKA. PIVKA-II (uncompletely carboxylated prothrombin) is not detected in 
plasma unless there is a defect in carboxylation attributable to impairment of 
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carboxylase enzyme and/or deficiency or antagonism of vitamin K. Determination of 
PIVKA-II by monoclonal antibody is a very specific and sensitive method (7). 
Although several authors stress the need for antenatal vitamin К supplementation to 
pregnant women on AC therapy to prevent HDN (2,4-6), the true incidence of 
vitamin К deficiency in these neonates is not known. For this reason, we performed 
an observational study to establish the incidence of vitamin К deficiency in mothers 
and infants exposed to AC drugs compared to controls. In 25 mother-infant pairs on 
AC therapy and in 25 control pairs, concentrations of vitamin K; and PIVKA-II 
were determined. 
73 MATERIAL AND METHODS 
Study population 
The study was approved by the medical ethical committee and after a full explana­
tion of the study protocol informed consent was obtained from all participants. 
Twenty-five pregnant epileptic women on AC treatment (mean duration 11 yrs, 
range 1-23 yrs) attending multicentre obstetric out-patient's departments and 25 
pregnant healthy controls attending a midwife practice, were recruited. Selection cri­
teria were: an uncomplicated pregnancy so far, no medication except for anticonvul­
sants in the epileptic group and folic acid, iron, and vitamins other than vitamin К 
in both groups. Complications and medication during follow-up, mode of delivery, 
and neonatal outcome were registered. Vitamin К was administered to the neonates 
after delivery according to local routine procedures. 
Laboratory determinations 
Maternal blood was sampled from the cubital vein at 32 weeks pregnancy and 
within two hours after delivery. Venous or mixed cord blood was sampled im­
mediately after cord clamping. At each sampling, 5 ml of citrated blood (in silicone 
coated tubes containing 10% (v/v) of sodium citrate 3.8% (w/v)) and 5 ml of 
coagulated blood were collected. The citrated blood was centrifuged (3500 χ g for 
10 min) and the removed plasma stored at -70oC until PIVKA-II was measured. 
The coagulated blood was protected from the light immediately after sampling, 
centrifuged (1000 χ g for 5 min) and the serum stored at -20oC for vitamin K^ 
determination. Samples from a mother-child pair were assayed in one run. All 
samples were coded to provide blind analysis. 
PIVKA-II concentrations were determined by an enzyme-linked immunosorbent 
assay, using a monoclonal antibody (Eitest mono P-II, Eisai, Tokyo, Japan) (8). This 
antibody quantitatively reacts with descarboxylated prothrombin (PIVKA-II) and 
does not cross-react with native prothrombin. PIVKA-II levels are expressed in 
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arbitraiy units (AU) per ml, so that 1 AU corresponds with 1 μg of purified 
prothrombin. РГ КА-ІІ levels in healthy adults, adults with liver cirrhosis and 
pregnant women are reported to be below 0.10 AU/ml, which is considered as the 
upper normal limit (9). In severe vitamin К deficiency PIVKA-II concentration can 
rise to more than 20 AU/ml (8). 
Vitamin K, was extracted from 1 ml serum samples by a two-step high performance 
liquid chromatographic (HPLC) procedure, according to the method of Lambert et 
al. (10, 11). A few modifications were applied. Recovery of vitamin K7 from 
standard solutions added to normal serum was 85 ± 5% with a detection limit of 30 
pg/ml. However, the detection limit of individual samples can vary from 30 to 130 
pg/ml, dependent on the recovery of internal standard during extraction and the 
amount of serum extracted. 
Statistical analyses 
x , Fisher's exact and Student t tests were used for comparison of study population 
characteristics and PIVKA-II results. Wilcoxon's one and two sample tests were 
applied to vitamin K¡ results. Spearman's rank correlation coefficient was used for 
correlation detection. 
7.4 RESULTS 
The two groups of mother-infant pairs were well comparable (Table 7.1). One 
pregnancy of the epileptic group resulted in unexplained fetal death at the 36th 
week of gestation. Unfortunately, it was not possible to collect cord blood of this 
Table 7.1 Characteristics of the study and control groups. 
Maternal age (y)* 
Nulliparae 
Gestational age (wk) 
Caesarean section 
Blood loss >1000 ml 
Neonatal sex, m:f 
Birth weight (g)* 
Apgar at 1, 5 min <7 
Epileptics 
28.2 (22-34) 
12 
40.1 (36.6-42.4) 
1 
1 
15:9 
3396 (2670-4750) 
2 ,2 
Controls 
29.4 (21-35) 
12 
40.1 (36.7-42.0) 
1 
3 
12:13 
3511 (2300-4500) 
2 ,0 
mean (range) 
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child, so he is not included in the results. His mother had no evidence of vitamin К 
deficiency. 
During follow-up two epileptic women were treated with Ritordine to prevent pre­
mature labour. They also developed pregnancy induced hypertension and PIVKA-II 
was detectable in their cord blood samples. Only one neonate showed indication of 
a bleeding diathesis, a child whose mother used 300 mg Phenytoin (DPH) daily and 
who developed a haematoma at the site of vitamin К injection. His Thrombotest 
one hour postpartum was 22% (normal 20-40). The PIVKA-II concentration in his 
cord blood was 1.47 AU/ml, while the vitamin Ky concentration was below the 
detection limit of 30 pg/ml. 
In epileptic women and controls PIVKA-II was not detectable at 32 weeks gest­
ational age, Table 7.2. At delivery, in 2 mothers who took Carbamazepine (CBZ) 
PIVKA-II was present in concentrations of 0.15 and 0.17 AU/ml. 
In the neonates who were intra-uterine exposed to AC drugs, PIVKA-II was detect­
able in 13 out of 24 samples (54%), including the neonates of the two PIVKA-II 
positive mothers; 3.20 and 0.60 AU/ml, respectively. In 5 (20%) control neonates 
PIVKA-II was detectable, but concentrations were low (Table 7.3). The higher rate 
of PIVKA-II detectability in the epileptic as compared with the control cord samples 
was statistically significant (p=0.01). Subgroups of AC are presented in Table 7.2. 
Remarkably, PIVKA-II was not detected in 4 neonates exposed to Valproic acid 
(VPA) monotherapy. This is statistically different from the other neonates of the 
epileptic group (0/4 against 13/20, p<0.05). 
In the control group all PIVKA-II positive cord samples were derived from Primi­
gravidae (p<0.01), who were significantly younger than the mothers of the PIVKA-II 
negative neonates (p<0.05). In the epileptic group such an association with parity or 
maternal age was not detected. 
The results of vitamin K^  determinations are depicted in Fig. 7.1. At 32 weeks of 
gestation vitamin K; concentrations (mean ± SD) amounted to 828 ± 548 pg/ml in 
the epileptic group and 1225 ± 787 pg/ml in the control group (p<0.05). At 
delivery maternal concentrations were decreased compared with levels at 32 weeks 
pregnancy; this was highly significant in the epileptic group (491 ± 256 pg/ml, 
p<0.01), but not significant in the control group (887 ± 401 pg/ml, p=0.07). At 
delivery maternal concentrations in the epileptic group were again significantly lower 
than in the control group (p<0.001). 
In cord blood vitamin K^  concentrations were predominantly below the detection 
limit: 22 out of 24 in the AC group and 17 out of 25 in the control group (NS). 
The other values are shown in Fig. 7.1. Vitamin K^  concentrations in the PIVKA-II 
positive cord blood samples are given in Table 7.3. The two epileptic mothers with 
PIVKA-II detectable at delivery had vitamin K ; levels of 512 and 189 pg/ml, 
respectively. 
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Table 7.2 PIVKA-II detectability (> 0.10 AU/ml) in mother-infant 
pairs with anticonvuhant (AC) therapy and in controls (n). 
GROUP 
CBZ 
CBZ + DPH 
CBZ + VPA 
DPH 
VPA 
PHB 
Mother 
32 wk 
0 (8) 
0 (1) 
0 (2) 
0 (1) 
0 (4) 
0 (4) 
delivery 
2(11) 
0 (1) 
0 (2) 
0 (2) 
0 (5) 
0 (4) 
Neonate 
cord blood 
6 (11) 
1 (1) 
1 (2) 
1 (2) 
0 (4) 
4 (4) 
Total AC 0 (20) 2 (25) 13 (24)* 
CONTROL 0 (25) 0 (25) 5(25) 
CBZ=carbamazepine, DPH=phenytoin, VPA=vaIproic acid, PHB=phenobarbital. 
* AC ν control group, ρ < 0.05. 
Table 7.3 PIVKA-II and corresponding vitamin Kj concentrations 
in cord blood samples with PIVKA-II detectable. 
GROUP PIVKA-II (AU/ml) Vitamin K.J (pg/ml) 
CBZ 
CBZ + DPH 
CBZ + VPA 
DPH 
PHB 
0.14 
3.20 
0.42 
1.35 
1.47 
0.20 
1.02 
0.60 
3.99 
0.26 
0.89 
4.54 
0.31 
b.d. 
b.d. 
b.d. 
b.d. 
b.d. 
b.d. 
82 
b.d. 
b.d. 
b.d. 
b.d. 
b.d. 
b.d, 
CONTROLS 0.14 0.14 0.18 b.d. 120 174 
0.19 0.28 b.d. b.d. 
b.d., below detection limit. 
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Neither a significant correlation was found between vitamin Kj and PIVKA-II 
concentrations, nor between these data and neonatal sex, gestational age, birth 
weight, Apgar score or maternal dose of AC. There was no significant difference in 
maternal vitamin K; plasma concentrations in the PIVKA-II positive and negative 
neonates for either groups. Vitamin K; levels were not significantly higher in women 
treated with VP A, as compared with those treated with other AC drugs. 
Vitamin K1 (pg/ml) 
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Fig. 7.1 Individual vitamin Kl plasma concentrations and means (—)in maternal blood 
at 32 weeks pregnancy and after delivery, and in cord blood, of mother-infant pairs on 
anticonvubant (AC) therapy and controL· (C). In the control group an outlier of 3997 
pg/ml at 32 weeks gestation L· not depicted. 
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7.5 COMMENT 
CBZ, DPH, PHB and VPA readily cross the placenta. Cord and maternal blood 
levels are almost the same or, as in VPA, the level is even higher in cord blood 
(12). DPH, PHB and CBZ induce microsomal mixed-function oxidase enzymes in 
the fetal liver and it is hypothesized that these hepatic enzymes increase the rate of 
oxidative degradation of vitamin К resulting in vitamin К deficiency (12, 13). Which 
of the many cytochrome P450 isozymes is involved in vitamin К metabolism is still 
not known. Bouwman et al. (14) reported an association between cytochrome P450 
IIB activity and vitamin К dependent coagulation, so induction of this cytochrome 
may be important in the pathogenesis of vitamin К deficiency. In this study VPA 
did not increase the rate of detectability of PIVKA-II in cord blood of exposed neo­
nates. This is in agreement with the fact that VPA does not induce hepatic enzymes 
(15). 
The finding that PIVKA-II was present in 20% of control cord blood samples is in 
agreement with the incidence of 21.5% in 102 normal cord blood samples reported 
by Motohara et al. (16) and 31% in 16 samples reported by Widdershoven et aL 
(17). They both used the same method as we did. Two other studies, applying other 
methods of detecting PIVKA-II, reported an incidence in control cord blood of 28% 
(18) and 36% (19). These percentages are quite higher than measured by Hulac et 
al. (20), who reported a rate of 3% in general population and 27% in newborns 
exposed to AC therapy. Despite this lower frequency, what might be due to the less 
sensitive method to determine PIVKA-II, their conclusion is similar; PIVKA-II is 
more frequently present in cord blood of neonates intra-uterine exposed to AC 
drugs than in control newborns. They agreed that PIVKA-II is rarely detectable in 
the mothers. 
Our results confirm that vitamin Kj concentrations in normal cord blood are very 
low, usually below the detection limit of the method used (17, 21). This extremely 
low level is probably caused by a placental barrier. Shearer et al. (22) reported 
concentrations of 144 to 2420 pg/ml in mothers and 4 - 4 5 pg/ml in cord blood, 
resulting in a median maternal-cord ratio of 30:1. An experimental study in pregnant 
rats has shown that diffusion across the placenta requires a high mother-fetus 
concentration gradient (23). After oral administration of vitamin Щ to pregnant rats, 
the amount of vitamin K; in the fetal liver is 1-2% of that in the maternal liver 
(24). Together with the frequent detection of PIVKA-II in cord blood, this shows 
that many neonates are in a state of borderline vitamin К deficiency. Few of these 
deficiencies proceed to clinical disease. In a subsequent study we have shown that 
administration of extra vitamin K.j via the mother prevented the appearance of 
PIVKA-II in cord blood (25). So, there is a direct relation between the availability 
of vitamin К and the presence of РГ КА-ІІ. 
I l l 
Vitamin К; plasma concentrations during normal pregnancy are reported to be 
normal (22) or slightly decreased (21). This study is the first to report levels for 
pregnant women on AC therapy. The concentrations appear to be decreased 
compared with those in control pregnant women, especially at delivery. This is 
supporting the hypothesis of an increased vitamin К turnover due to induction of 
hepatic enzymes by the AC drugs. The decrease of maternal vitamin K; plasma 
levels, however, is probably in the majority of cases not severe enough to impair 
maternal carboxylation of vitamin К dependent coagulation factors. In addition, 
adults can utilize abundant hepatic stores of vitamin K2 (menaquinones) as cofactor 
for the carboxylation process. On the contrary, vitamin K2 is not detectable in the 
first two weeks of life in the neonatal liver (26). With the placental barrier ham­
pering transport of vitamin Ky, it is conceivable that fetuses of mothers on AC 
therapy are even more prone to develop vitamin К deficiency than normal new-
boms, as confirmed by our PIVKA-II results. 
The finding that maternal vitamin K^  plasma concentrations immediately after 
delivery are lower than at late-trimester pregnancy, may be related to fasting. 
Usually, women scarcely eat several hours during labour and it has been established 
that fasting concentrations of vitamin Щ are lower than non-fasting levels (22). 
The present paper is the first documentation of simultaneous measurements of both 
vitamin Kj and PIVKA-II in mother-infant pairs on AC medication. Both para­
meters are necessary for a precise evaluation of vitamin К status. In conclusion, the 
results of this study point to an increased incidence of subclinical vitamin К 
deficiency in neonates of mothers who are treated during pregnancy with enzyme-
inducive AC drugs. The women themselves have decreased vitamin K^ plasma con­
centrations, but are not frequently vitamin К deficient. Whether vitamin К prophy­
laxis after birth can prevent early haemorrhagic disease in neonates intra-uterine 
exposed to AC drugs is doubted, though it may not be dispensed with (3). In a 
subsequent study we investigated whether antenatal supplementation of vitamin К to 
pregnant women on AC therapy, can reverse the increased incidence of vitamin К 
deficiency in their neonates (25). 
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8.1 ABSTRACT 
Objective - The null hypothesis of this study is; extra vitamin К administered to 
pregnant women on enzyme-inducive anticonvulsant therapy will not decrease the 
frequency of signs of vitamin К deficiency in their neonates. 
Study design - Multicenter case-control study. Sixteen pregnant women on anticon­
vulsant therapy received daily 10 mg vitamin K; from 36 weeks of gestation 
onwards. PIVKA-II and vitamin Kj concentrations were determined in cord blood 
and compared with 20 controls. 
Results - In 0/17 cord samples PIVKA-II was detectable compared with 13/20 in 
controls (χ2, p<0.001). Median cord vitamin K7 concentration was 530 pg/ml 
compared with concentrations below the detection limit in most controls. 
Conclusions - Antenatal vitamin Kj treatment decreases the frequency of vitamin К 
deficiency in neonates of mothers on en2yme-inducive AC therapy. 
8.2 INTRODUCTION 
The activity of vitamin K-dependent coagulation factors in neonates is lower than in 
adults. Severe haemorrhagic disorders have been reported in young infants suffering 
from vitamin К deficiency (1). Therefore, the Committee on Nutrition of the 
American Academy of Pediatrics has recommended that prophylactic vitamin К be 
administered to all newborns (2). The incidence of haemorrhagic disease of the 
newborn declined dramatically in Japan due to vitamin К prophylaxis (3). 
Newborns exposed in utero to anticonvulsant (AC) drugs are most at risk for 
vitamin К deficiency (4). We reported that proteins induced by vitamin К absence 
(PIVKA-II; precursor prothrombin; descarboxylated prothrombin), which are a bio­
chemical marker of subclinical vitamin К deficiency, were significantly more 
frequently detectable in cord blood of newborns prenatally exposed to AC drugs 
than in controls, especially if enzyme-inducive drugs were involved. In addition, cord 
blood concentrations of vitamin K; were predominantly below the detection limit 
(4). Many reports have been published on haemorrhages in infants whose mothers 
took AC medication during pregnancy. Some of these occurred despite vitamin К 
prophylaxis at birth (5-7). Intrapartum or early neonatal haemorrhages may not be 
prevented by postnatal administration of vitamin K. In this regard, prenatal ad­
ministration of vitamin К might be worthwhile. Therefore, we studied the effect of 
vitamin Kj supplementation by measuring plasma vitamin K¡ and PIVKA-II concen-
trations in mother-neonate pairs on AC therapy who were supplemented with extra 
vitamin K¡ during the last month of pregnancy and compared these concentrations 
with controls. 
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S3 MATERIAL AND METHODS 
Study population 
The study was approved by the medical ethical committee and after full explanation 
of the study protocol written informed consent was obtained from all participants. 
Thirty-six pregnant epileptic women on AC therapy (median duration 12 years, 
range from 1 to 31) attending multicentre obstetric out-patient's departments were 
involved. Only AC drugs known to induce microsomal hepatic enzymes, like Phéno-
barbital (PHB), Phenytoin (DPH), Carbamazepine (CBZ) and Primidone (Prim) 
were included. Other selection criteria were: an uncomplicated pregnancy so far and 
no medication except for anticonvulsants, folic acid, iron and vitamins other than 
vitamin K. The subjects were divided into two groups: 16 patients were supple-
mented with vitamin K; (Konakion^, Hoffmann-La Roche) 10 mg/day orally from 
the 36th week of gestation until delivery (mean 29 days, range from 10 to 46). Date 
and time of intake were recorded. The final dose was ingested before delivery 
(mean 20 hours, range from 6 to 39). The other group of 20 women did not receive 
extra vitamin К and served as controls. The groups were studied consecutively, as 
the latter group was derived from 25 patients previously described (4). Valproic acid 
(VPA) was excluded because VPA does not induce microsomal enzymes (8), and 
hence does not increase the frequency of neonatal vitamin К deficiency (4). 
Characteristics of the two groups of mother-infant pairs are given in Table 8.1. One 
mother delivered a twin. Maternal age at delivery was higher in the supplemented 
group than in the control group (p<0.05). The other parameters did not differ sig­
nificantly between the groups. 
Laboratory determinations 
Venous or mixed cord blood was sampled immediately after cord clamping. Within 
two hours after delivery blood was sampled from the cubital vein of the mother. 
Five ml of citrated blood (in silicone-coated tubes containing 10% (v/v) of sodium 
citrate 3.8% (w/v)) and 5 ml of coagulated blood were collected. The citrated blood 
was centrifuged (3500 χ g for 10 min) and the removed plasma stored at -7(fC until 
PIVKA-II was measured. The coagulated blood was protected from the light 
immediately after sampling, centrifuged (1000 χ g for 5 min) and the senim stored 
at - 2 0 ^ for vitamin Kj determination. Samples from a mother-child pair were 
assayed in one run. All samples were coded to provide blind analysis. 
PIVKA-II concentrations were determined by an enzyme-linked immunosorbent 
assay, using a monoclonal antibody (Eitest mono P-II, Eisai, Tokyo, Japan) (9). This 
antibody quantitatively reacts with descarboxylated prothrombin (PIVKA-II) and 
does not cross-react with native prothrombin. The detection limit was 0.10 AU/ml. 
Vitamin K; was extracted from 1 ml serum samples by a two-step high performance 
liquid chromatographic (HPLC) procedure, according to the method of Lambert eC 
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aL (10, 11). A few modifications were applied, as stated elsewhere (4). Recovery of 
vitamin K.J from standard solutions added to nonnal serum was 85 ± 5% with a 
detection limit of 30 pg/ml. However, the detection limit of individual samples can 
vary, dependent on the recovery during extraction and the amount of serum 
extracted. 
Statistical analyses 
x , Fisher's exact and Student / tests were used for comparison of study population 
characteristics and РГ КА-ІІ results. Wikoxon's one and two sample tests were 
applied to the vitamin Kj results. Spearman's rank correlation coefficient was used 
for correlation detection. 
Table 8.1. Characteristics of the study and control groups. 
Mothers (n) 
Maternal age (y) 
Nulliparae 
Gestational age (wk) 
Caesarean section 
Blood loss > 1000 ml 
Neonates 
Neonatal sex, m:f 
Birth weight (g)* 
Apgar at 1, 5 min <7 
Study group 
16 
31.0 (21-38) 
9 
39.7 (36.6-41.9) 
2 
4 
11:6 # 
3161 (2410-3720) 
3,1 
Control group 
20 
28.6 (25-34) 
7 
40.1 (36.6-42.0) 
1 
1 
13:7 
3452 (2690-4750) 
2,2 
* mean (range) * one pair of twins included 
8.4 RESULTS 
Except for one neonate with fetal hydantoin syndrome, all neonates were healthy 
and no bleeding tendencies were recorded. 
PIVKA-II results are shown in Table 8.2. In both supplemented and control pregnant 
women on AC therapy, PIVKA-II was detectable rarely. In cord blood of control 
neonates PIVKA-II was detected in 13 out of 20 samples (65%), with concentrations 
ranging from 0.14 to 4.54 (median 0.89) AU/ml. On the contrary, in the supple­
mented group 0 out of 17 samples had PIVKA-II detectable (p<0.001). Various 
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subgroups of AC are distinguished in Table 8.2. The difference in the presence of 
PIVKA-H in cord blood between the supplemented and control group was statisti­
cally significant for CBZ monotherapy (p<0.05), CBZ with other medication 
(p<0.01) and PHB monotherapy (p<0.05). The number of individuals in the other 
subgroups was too small for statistical analysis. 
Table 8.2 PIVKA-II detectability (> 0.10 AU/ml) in vitamin К supplemented (suppl) 
and control mother-infant pairs on AC therapy during pregnancy (n). 
GROUP 
CBZ 
CBZ + DPH 
CBZ + VPA 
CBZ + PHB 
DPH 
PHB 
PHB + VPA 
Total 
control 
2(11) 
0 (1) 
0 (2) 
-
0 (2) 
0 (4) 
--
2(20) 
Mother 
suppl 
0(5) 
0(2) 
0(1) 
0(1) 
0(2) 
0(4) 
+ 
0(15) 
control 
6(11) 
ι (i) 
1 (2) 
-
1 (2) 
4 (4) 
--
13 (20) 
Neonate 
suppl 
0 (6) # * 
0 (2) 
0 (1) 
0 (1) 
0 (2) 
0 ( 4 ) * 
0 (1) 
0 (17) * 
CBZ=carbamazepine, DPH=.phenytoin, VPA=valproic acid, PHB=phénobarbital. 
*, one pair of twins included. 
*, suppl. ν control group, p<0.05. 
*, one value missing due to sampling error. 
The median maternal vitamin Kj concentration in the control group was 389 pg/ml 
(range from 139 to 1265) as compared with 22,760 pg/ml (range from 5630 to 
111,460) in the supplemented group, (p<0.001). 
In cord blood of control neonates vitamin K; was hardly detectable. The concentra­
tion was below the detection limit in all but one sample with 82 pg/ml. In contrast, 
in the supplemented neonates the vitamin K^ concentration was always above the 
detection limit and ranged from 218 to 894 pg/ml, with an outlier of 1618, median 
530 pg/ml. Maternal supplementation thus increased cord vitamin Kj concentration 
at least 15 times. The ratio maternal/neonatal concentrations ranged from 10 to 128, 
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with an outlier of 511, median 44. The twin's vitamin K; concentrations were 530 
and 716 pg/ml, while their mother's concentration was 21,640 pg/ml. 
Although maternal vitamin Kj concentrations were negatively correlated with time 
elapsed since the last vitamin Kj intake (r=-0.64, p=0.005, n=14), they were not 
correlated with total duration of treatment (r=0.10, p=0.36) n=16). Cord blood 
concentrations tended to correlate with the time elapsed since the last vitamin K.j 
ingestion (r=-0.42, p=0.07, n=14), but were not correlated with the total duration 
of therapy (r=-0.12, p=0.33, n=17). 
8.5 COMMENT 
Placental transfer of vitamin К is hampered. A high maternal-fetal concentration 
gradient is required for diffusion across the placental barrier (12). Shearer et al. (13) 
reported concentrations of 144 to 2420 pg/ml in healthy mothers and 4-45 pg/ml in 
cord blood, resulting in a median maternal-cord ratio of 30:1. Our concentrations of 
139 to 1265 pg/ml in unsupplemented mothers on AC therapy are comparable, or as 
demonstrated in our previous publication, slightly lower than in controls (4). In 
unsupplemented neonates exposed in utero to AC drugs, cord vitamin Kj concen­
trations were predominantly below the detection limit, like in control newborns (4). 
Maternal supplementation with an oral dose of 10 mg vitamin K^ daily raised the 
median maternal vitamin K^  concentration some 60-fold and the median cord con­
centration at least 15-fold. Our median maternal-cord ratio was 44. The outlying 
ratio of 511 was derived from a mother-neonate pair of whom the mother had 
ingested the last vitamin К dose only 6 hours prior to sampling. Correspondingly, 
the mother had the highest maternal concentration and the cord the lowest cord 
concentration of all. 
Other studies confirm placental transfer of vitamin Ky after supplementation of the 
mother, unless it is administered at least 4 hours before delivery (12,14,15). Owen et 
aL (16) concluded from a double blind study of 204 infants that prenatal oral 
administration of vitamin Kj (5 mg/day for 12 days) exerted a beneficial effect on 
the relative deficiency of prothrombin that normally exists in the newborn infant. No 
undesirable side effects were encountered. Correspondingly, Deblay et al. (17) 
reported a decrease from 27 to 0% of neonatal subnormal prothrombin concentra­
tions assayed by Quick's method, after treatment of pregnant epileptic women with 
20 mg vitamin Kj daily for 2 weeks. Mandelbrot et al. (18) performed a study of 
antenatal supplementation in non-epileptic mother-infant pairs. The mean maternal 
concentration increased to 45,190 pg/ml and the mean neonatal concentration to 783 
pg/ml after administration of 20 mg vitamin K; daily for 3-7 days. The maternal-
cord ratio was 44, similar to our ratio. Despite the resulting higher vitamin Kj 
concentrations, there are as yet no reasons to prefer the administration of 20 mg 
over 10 mg daily. Kazzi et aL (15) demonstrated that cord vitamin Kj concentrations 
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were higher in infants whose mothers received oral vitamin K; daily, than in infants 
whose mothers received an intramuscular injection every four days. Because neither 
Kazzi et al. (15), nor Mandelbrot et aL (18), nor we, could detect a correlation 
between maternal or cord vitamin Kj concentrations and total duration of 
treatment, duration of therapy seems not important to elevate vitamin K; 
concentrations in cord blood. The correlations between the time elapsed since last 
vitamin К ingestion and maternal or cord vitamin K¿ Iconcentrations, demonstrate 
that vitamin К ; plasma levels decline rapidly after administration of pharmacological 
doses of vitamin K;. 
Another parameter for defining vitamin К status is determination of PIVKA-II. 
Detection of this protein indicates that not all prothrombin is carboxylated com­
pletely. Due to a long disappearance time PIVKA-II can still be present after the 
deficiency has been corrected. This study shows that vitamin К supplementation 
abolishes the presence of PIVKA-II, so detection of PIVKA-II seems a specific 
indicator of vitamin К deficiency. Low amounts of PIVKA-II have no clinical con­
sequences, but they tell us which group of infants is most at risk for vitamin К 
deficiency. An additional burden may lead to bleeding diathesis and haemorrhages. 
The present study is the first to report PIVKA-II concentrations in mother-infant 
pairs on AC therapy with and without supplementation of vitamin Ky. A comparable 
study in non-epileptic mother-infant pairs has been reported: PIVKA-II was not 
detected in any of the supplemented neonates as compared with 20% of the control 
newborns (14). In a previous paper we also found in 20% of control newborns 
PIVKA-II present (4). However, in neonates exposed to AC drugs the incidence was 
increased to 54%. Excluding VPA medication, the frequency was even 65%. Except 
for an higher frequency of PIVKA-II detectability, PIVKA-II concentrations were 
higher in infants exposed to enzyme-inducive AC drugs than in controls (4). The 
present study demonstrates that after antenatal vitamin K; supplementation PIVKA-
II was not detectable in cord plasma. Consequently, under these conditions all 
prothrombin seems to be completely carboxylated. Antenatal vitamin К prophylaxis 
will probably diminish the risk of neonatal haemorrhages related to vitamin К 
deficiency. Administration of vitamin К resulted in high maternal vitamin K; blood 
concentrations, but adverse effects were not reported. It remains unknown what 
would be the best dosage to prescribe. 
The existence of elevated vitamin K; cord blood concentrations and disappearance 
of PIVKA-II after maternal ingestion of vitamin K^  confirms that prenatal prophy­
laxis of vitamin К deficiency is possible. Such a treatment is indicated to protect 
fetuses and newborns whose mothers receive medication that induce vitamin К 
deficiency. The pathogenetic mechanism by which anticonvulsants induce vitamin К 
deficiency is not established yet. PHB, DPH and CBZ induce microsomal mixed-
function oxidase enzymes in the fetal liver and it is hypothesized that these enzymes 
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increase degradation of vitamin К (19). In the rabbit administration of PHB 
increased plasma clearance of vitamin K ; (20), but this was not confinned in a 
small group of human adults (21). However, the degree of enzyme induction might 
be higher in fetuses, who normally have low activity of microsomal enzymes, as 
compared with adults. Since fetal plasma levels of vitamin K ; are already low, it is 
conceivable that some extra degradation of vitamin К results in vitamin К deficien­
cy. Which of the cytochrome P450 isozymes is involved in vitamin K's metabolism is 
not known. Bouwman et al (22) reported an association between cytochrome P450 
IIB activity and vitamin K-dependent coagulation in rats. In our previous study we 
showed that VPA did not increase the rate of PIVKA-II detection in cord blood of 
exposed neonates (4). This is in agreement with the fact that VPA is not enzyme 
inducive (8). Other hypotheses how anticonvulsants could induce vitamin К deficien­
cy, are hampering of placental transfer of vitamin К and inhibition of the car­
boxylase system (6, 21). 
Although recommendations on antenatal vitamin К therapy will stand for unneces­
sary treatment of many, each intracranial haemorrhage with fatal or serious sequela 
in otherwise normal children must be prevented. Therefore, we recommend vitamin 
Kj supplementation during the last days of pregnancy in mothers on enzyme-
inducive AC therapy to prevent vitamin К deficiency in their neonates. 
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9. SUMMARY AND GENERAL DISCUSSION 
Vitamin К serves as a cofactor for the vitamin K-dependent carboxylase enzyme, 
which is involved in the production of coagulation factors II, VII, IX, X, and 
coagulation inhibitors protein С and protein S (chapter 1). The carboxylation of 
specific glutamic acid residues to γ-carboxyglutamic acid residues confers unique 
calcium binding properties upon these proteins which are essential for an effective 
haemostatic function. When carboxylation is impaired because of a deficiency or 
antagonism of vitamin K, inert precursors of the coagulation factors appear in the 
blood. These are called "proteins induced by vitamin К absence (PIVKA)". PIVKA-
II (des-carboxylated prothrombin) is a sensitive indicator of vitamin К deficiency, 
chapter 2 (1). Although biochemical vitamin К deficiency is of no clinical impor­
tance, it is of value in assessing which group of infants risks developing haemorrhage 
due to vitamin К deficiency. 
Vitamin К deficiency results in a depletion of functional coagulation factors II, VII, 
IX and X, leading to a generalized bleeding tendency. In infancy three bleeding 
syndromes are differentiated: early haemorrhagic disease of the newborn (HDN) 
within 24 hours after birth, classical HDN at the age of 2 to 7 days, and late HDN 
after the first week of life (2, 3). Especially early and late HDN are often located 
intracranially, with a fatal or adverse late outcome. 
Administration of vitamin К to neonates for the prevention of HDN has become 
widespread. However, controversies still exist over the need for a general vitamin К 
prophylaxis and over the best route, frequency and dose of vitamin К to be used 
(4). The aim of this study was to establish recommendations for the prevention of 
vitamin К deficiency in otherwise healthy, normal infants. 
9.1 VITAMIN К PROPHYLAXIS IN GENERAL 
The best prophylaxis is to eliminate the cause of vitamin К deficiency. Unfortu­
nately, this is impossible for several reasons. First, in many cases the cause of the 
deficiency is unresolved (2). Next, in cases with an underlying disease, the cause 
frequently cannot be eliminated (5) or is only discovered after the bleeding episode. 
Some contributing factors in the aetiology of idiopathic HDN are discussed in 
chapter 1. Most important factors seem to be a dietary deficiency of vitamin K ;, 
especially in breast-fed infants, and subclinical fat malabsorption. Motohara et al. (6) 
as well as von Kries et al. (7) reported that the total amount of milk intake during 
the first few days of life was significantly lower in infants who were positive for 
PIVKA-II than in those negative for PIVKA-II. Administration of 15 /jg vitamin YLj 
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after birth prevented the appearance of PIVKA-II during the first few days of life 
(6). This corresponds with the recommended dietary intake (RDI) of 5 /ig/day for 
children up to the age of 6 months (8). Since the vitamin K; content of human milk 
is about 2 /ig/l (paragraph 1.4.2) the needs of the breast-fed human infant are 
obviously not met. Greer et aL (9) reported that the vitamin K; intake of breast-fed 
infants is approximately 0.6 Mg/day, while formula-fed infants ingest as much as SO 
pg daily. In other words, vitamin Kj intake of breast-fed infants is some 100 times 
lower than that of formula-fed infants. The latter rarely develop symptoms of 
vitamin К deficiency beyond the neonatal period (3,7,10). In some breast-fed infants 
with late HDN, the vitamin Kj content of their mothers' milk was found to be 
subnormal (11,12,13), in others however it was normal (13). Supplementation of 
extra vitamin К for breast-fed infants therefore seems reasonable. Some prefer 
supplementation via breast-milk by dietary advise to the mother. However, more 
research is needed to establish the efficacy of such a regimen. 
The presence of dioxins and related xenobiotics in breast-milk in industrial countries 
was hypothesized as a cause of late HDN. Koppe et aL (14) reported that the mean 
dioxin content in maternal milk of 4 vitamin K-deficient infants with clinical bleeding 
was higher than in that of 10 healthy infants. Comparable to the situation for 
enzyme-inducive anticonvulsants, which cause early HDN, dioxins may induce micro­
somal enzymes in the neonatal liver and hence increase degradation of vitamin К 
(14, 15). Additionally, these xenobiotics might disturb the intestinal flora and impair 
the production of vitamin K2. More research into the causes of HDN is wanted. 
9.2 SAFETY OF VITAMIN К PROPHYLAXIS 
Before recommendations on vitamin К prophylaxis are justified, it must be certain 
that the administration of extra vitamin К is safe. As discussed in paragraph 1.9.1, 
there is some concern about a possible carcinogenic risk of the intramuscular 
administration of vitamin К during early life (16). In fetal sheep lymphocytes an 
increase in sister chromatid exchanges (SCE) was seen after injection of vitamin Kj 
(17). In order to determine whether there are indications that vitamin Kj may have 
genotoxic or carcinogenic effects in the human neonate, we performed two short-
term mutagenicity tests (chapter 3). Neither SCE nor chromosome aberrations 
showed an increase in the peripheral blood lymphocytes of newborns 24 hours after 
the administration of 1 mg vitamin K^  intramuscularly. Thus, we did not find any 
evidence of genetic toxicity due to administration of 1 mg vitamin Kj to the 
newborn infant, but long-term tests are needed as well. 
130 
93 PREVENTION OF CLASSIC AND LATE HAEMORRHAGIC DISEASE OF 
THE NEWBORN 
Vitamin К prophylaxis was introduced to protect infants against classic HDN and its 
efficacy has been established beyond doubt (18, 19). Jörgenson et aL (20) and 
O'Connor et aL (21) demonstrated that oral administration of vitamin К is as 
effective in the prevention of classic HDN as intramuscular injection, but follow-up 
was too limited to conclude about prevention of late HDN. It is doubtful whether 
all cases of late HDN are prevented by a single administration after birth (3). In 
Table 1.6 (chapter 1) 104 cases of late HDN despite vitamin К prophylaxis at birth 
are cited: 93 cases following oral vitamin К administration and 11 after intra­
muscular administration. Nevertheless, it must be emphasized that most case-reports 
of late HDN occurred in infants who had not received prophylaxis. To establish 
recommendations for the prevention of late HDN, we conducted three prospective 
studies (chapters 4, 5 and 6). Results of PIVKA-II and vitamin Ky determinations 
from these studies and from the literature are summarized in Tables 9.1 and 9.2. 
Table 9.1 Presence of PIVKA-II (>0.10 AU/ml) in serum of infants at different ages 
(n); influence of feeding regimen and vitamin К supplementation. 
FORMULA 
no vit К 
BREAST 
no vit К 
BREAST 
1 mg oral 
BREAST 
1 mg i.m. 
BREAST 
1 mg weekly 
BREAST 
25
 Mg daily* 
(Ref) 
(9)" 
(9)" 
(ch4) 
(ch4) 
(ch5) 
(Ch6) 
2 
„ 
-
0(165) 
0(166) 
--
-
Weeks after birth 
4 
0(49) 
4(73) 
3(135) 
1(127) 
0(42) 
0(48) 
8 
0(48) 
4(44) 
-
--
0(41) 
0(49) 
12 
0(52) 
3(40) 
7(68) 
8(63) 
0(43) 
0(50) 
a
 Reported by Widdershoven et aL, who applied a detection limit of 0.13 AU/ml. 
b
 In addition to 1 mg vitamin K1 orally or intramuscularly (i.m.) after birth. 
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Table 9.2 Mean vitamin Kj concentrations (pg/ml) in formula-fed and breast-fed 
infants with and without vitamin К supplementation. 
FORMULA, no vit К 
BREAST, no vit К 
BREAST, 1 mg oral 
1 mg i.m. 
1 mg i.m. 
1 mg i.m. 
1 mg weekly" 
25
 Mg daily* 
(Ref) 
(Ch6) 
(10) 
(22) 
(9) 
(10) 
(22) 
(ch4) 
(ch4) 
(10) 
(9) 
(ch5) 
(Ch6) 
η 
10 
7 
8 
11 
12 
10 
74 
64 
13 
23 
25 
32 
Weeks after birth 
2 
815 
1608 
4 
7044 
2890 
4450 
707 
490 
391 
615 
698 
1223 
1972 
8 
7885 
927 
1371 
12 
6040 
5580 
268 
329 
200 
748 
1068 
a
 Vitamin K, concentrations 6 to 7 days after the latest administration. 
b
 In addition to 1 mg vitamin K^ oral or i.m. after birth. Vitamin K, concentrations 20 to 28 hours 
after the latest administration. 
Oral versus intramuscular vitamin К prophylaxis at birth 
In chapter 4 two groups of about 165 breast-fed infants were randomized to receive, 
either orally or intramuscularly, 1 mg vitamin Kj on the first or second day of life. 
Although vitamin K; plasma concentrations were significantly higher in the intra­
muscular group, Thrombotests, activities of clotting factors VII and X, and PIVKA-
II concentrations did not reveal any difference between the two groups. At the age 
of 2 weeks vitamin K; concentrations were still elevated in comparison with 
reported levels in unsupplemented infants and PIVKA-II was not detectable, 
indicating that both prophylactic regimens were still effective at that age. At the age 
of one month vitamin K^ concentrations had declined to unsupplemented levels, 
while PIVKA-II was detectable in few infants. Comparison of our results with those 
of Widdershoven et al (10) revealed that intramuscular vitamin К still has an effect 
at the age of one month, while oral vitamin К does not. However, at 3 months of 
age 11.5% of infants had PIVKA-II in their blood, demonstrating that neither 
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prophylactic regimen was completely effective at that age. Other reports confirm the 
reappearance of PIVKA-II after a single administration at birth (10, 23). Taking 
both these results and epidemiological evidence into account, it can be concluded 
that for a complete protection of breast-fed infants against the risk of late vitamin К 
deficiency, the administration should be repeated. In chapters 5 and 6, weekly and 
daily repeated administrations were evaluated. 
The infants in whose blood PIVKA-II was detectable did not differ from the infants 
without РГ КА-ІІ for Thrombotest results and activities of clotting factors VII and 
X (Table 4.3). However, these conventional coagulation parameters are not sensitive 
to a biochemical vitamin К deficiency (1). Haemostasis is not yet impaired in 
persons with low concentrations of PIVKA-II. Vitamin K/ concentrations were not 
different in PIVKA-II positive infants as compared with PIVKA-II negative ones. 
This might be explained as follows. First, because PIVKA-II has a long half-life, it 
can still be present after the deficiency has been corrected (paragraph 2.2). Sec­
ondly, plasma concentrations of vitamin K; vary widely, dependent on the time 
elapsed since the latest vitamin Kj intake. The plasma half-life of tritiated vitamin 
Kj has been reported to be about 2.5 hours (24, 25). Further, besides vitamin K^ 
vitamin K2 is present in the human liver after the second week of life (26). Vitamin 
K2 consists of different menaquinones (MK's) produced by certain intestinal 
bacteria. In vitro, MK-2 to MK-6 have been shown to be as active as vitamin Kj as 
cofactor for the carboxylase enzyme (27). Maybe a deficiency of vitamin K2 might 
cause a biochemical vitamin К deficiency regardless of vitamin K^ status. 
Determination of vitamin K2 status is complicated since many MK's must be ac­
counted for. To our knowledge, vitamin K2 plasma concentrations in infancy have 
not been reported so far. We succeeded in determining MK-3 to MK-7 by HPLC 
procedure and applied this to 30 blood samples of formula-fed infants and 134 
samples of breast-fed infants. The preliminary results indicate that more different 
MK's and higher concentrations of MK's are present in formula-fed infants. For 
example, mean concentrations of MK-5, MK-6, and MK-7 amounted to 659 ± 433, 
1854 ± 1032, and 2994 ± 2557 pg/ml, respectively in the formula-fed group, while 
in the breast-fed group MK-5 and MK-7 were not even detectable. MK-6 amounted 
to 668 ± 630 pg/ml in this latter group. Differences in intestinal flora between 
human milk-fed and artificial milk-fed infants have been reported, resulting in a 
lower vitamin K2 production in the former group (28). Our results indicate that the 
vitamin K2 supply may be an important additional factor in the aetiology of HDN. 
This offers an extra explanation for the fact that vitamin Щ and PIVKA-II con­
centrations are not correlated. On the contrary, PIVKA-II is a direct reflection of 
the availability of all vitamin К for the carboxylation of prothrombin. As will be 
shown in the next paragraphs, supplementation of vitamin K, prevented the appear­
ance of PIVKA-II. We conclude that determination of PIVKA-II is more suitable 
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for assessing vitamin К status than vitamin K, plasma concentrations. Altogether, 
determination of MK's has opened a new field of research. 
Weekly vitamin К prophylaxis in breast-fed infants 
In chapter 5, 48 breast-fed infants weekly received an oral dose of 1 mg vitamin Щ. 
No symptoms of vitamin К deficiency occurred; all mfants had normal Thrombotest 
results and PIVKA-II was not detectable. At the age of 12 weeks, the detection rate 
of PIVKA-II was significantly lower than in infants who had received a single dose 
of vitamin K; postnatally. So, weekly administration of 1 mg vitamin Kj seems 
reliable to prevent late signs of vitamin К deficiency. As was to be expected, vitamin 
Kj concentrations showed a negative correlation with the number of days elapsed 
since the latest vitamin К administration. After 6 to 7 days, concentrations ranged 
from 278 to 2530 pg/ml. Mean values were significantly higher than in infants who 
received a single dose at birth. A weekly dose of 1 mg corresponds to a daily dose 
of approximately 150 μg. This exceeds by far the RDI of 5 pg/day and is 3 times the 
presumed dosage ingested by formula-fed infants. However, vitamin Kf plasma con­
centrations in formula-fed infants were higher (Table 9.2). But the levels in weekly 
supplemented infants probably fluctuate more than those in formula-fed infants, who 
continually receive small doses of vitamin K .^ No harmful effects of temporarily high 
vitamin K; plasma concentrations have been reported so far, nor have they been 
discovered in our cytogenetic study reported in chapter 3. Since 1985 weekly oral 
administration of 1-2 mg vitamin K^ to breast-fed infants has been recommended in 
France and no case of late HDN has been reported so far (29). In 1986 the 
German Paediatric Society recommended to administer 1 mg vitamin K^ twice 
weekly when parenteral application was rejected by the parents (30). In these 
children concentrations were very high when measured 24 hours after the adminis­
tration (>10 ng/ml), and were in the range of formula-fed infants after 72 hours 
(31). Our results demonstrate that administration once per week is equally effective. 
Perhaps still lower doses are adequate. 
Daily vitamin К prophylaxis in breast-fed infants 
Formula-feeding seems effective to prevent late vitamin К deficiency, as case-reports 
of late HDN in formula-fed infants are rare, PIVKA-II is never detectable and 
vitamin К; plasma concentrations are high (10). Supplementation of breast-fed 
infants to an amount comparable to the dose ingested by formula-fed infants would 
be a logical approach. No studies evaluating such low doses have been performed. 
In chapter 6, 58 breast-fed infants who were supplemented daily with 25 pg vitamin 
Kj, as well as 10 infants who were fed with a formula containing at least 50 pg/l vit­
amin Kf, are reported. The daily supplements prevented the appearance of PIVKA-
II (Table 9.1). Vitamin Щ concentrations in these infants were not correlated with 
the number of days of vitamin K¿ treatment, but indeed were negatively correlated 
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with the number of hours elapsed since the latest vitamin К administration. After 20 
to 28 hours concentrations ranged from 112 to 9023 pg/ml. Again, concentrations 
varied widely between individuals. Mean values were significantly higher than in 
unsupplemented infants, but were significantly lower than in formula-fed infants 
whose values ranged from 3028 to 10,884 pg/ml. This is in accordance with the fact 
that a daily intake of 25 /ig vitamin Kj exceeds by far the presumed intake of about 
1 fig/day for unsupplemented breast-fed infants and is about half the dose ingested 
by formula-fed infants. The RDI of 5 /ig/day is generously met. It can be concluded 
that the suggested maintenance dose is reliable for the prevention of late vitamin К 
deficiency in breast-fed infants. Whether lower doses are also suitable is unknown at 
present. Again, no accumulation of vitamin K; was discovered. On the contrary, 
concentrations declined during follow-up, probably because the volume of distribu­
tion increases with age. 
Whether a daily or a weekly regimen should be preferred is subjective. Mean con­
centrations prior to the next administration were slightly higher in the daily supple­
mented group than in the weekly group, although not statistically significant. In the 
daily supplemented group the range of vitamin K^  concentrations was wider, but 
evidently all infants had enough vitamin К available for the carboxylation process, as 
no PIVKA-II was present. In practice, daily administration of vitamin К soon will be 
routine for the parents, while a weekly administration is likely to be easily forgotten. 
When an administration is forgotten or the drug is spat out unnoticed, this has 
fewer lasting consequences for the daily regimen. The total dose administered in the 
daily regimen amounts to 2.1 mg versus 12 mg in the weekly regimen. We suggest to 
recommend 1 mg vitamin Kj either orally or intramuscularly after birth in all 
newborn babies, followed by a daily administration of 25 ^g vitamin Kj from 2 
weeks until 3 months of age in breast-fed infants. Current Dutch recommendations 
start at the age of one week (32), but it is doubtful whether this is necessary. As 
reported in chapter 4, a single administration of 1 mg vitamin K7 at birth is still 
effective after 2 weeks. The limit of 3 months is also arbitrary. We did not study 
our subjects beyond this period. Late HDN, however, is rarely reported beyond the 
age of 3 months (3). The low rate of exclusive breast-feeding as well as availability 
of vitamin K2 may partly account for this. 
Vitamin К prophylaxis in infants exposed to coumanns 
A group of infants especially at risk of vitamin К deficiency-haemorrhage, is that 
exposed to 4-hydroxy-coumarins. When a lactating mother takes these anticoagu­
lants, her baby is exposed via the milk. Extra vitamin К supplementation to the 
child has been recommended to overcome the vitamin К antagonism. We studied 
vitamin K^ concentrations in 4 infants who were exposed to acenocoumarol (Sin-
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trom^) and were prescribed 1 mg vitamin К^ per day. Vitamin K; concentrations 
were extremely high: 67.4 ± 46.0 ng/ml. Lower doses are to be recommended. 
9.4 PREVENTION OF EARLY HAEMORRHAGIC DISEASE OF THE NEWBORN 
Another group of infants at risk of vitamin К deficiency-haemorrhage is that 
exposed to anticonvulsants (AC). More than 40 case-reports have been published on 
haemorrhages in neonates bom to mothers treated with AC (33). These bleedings 
occur within 24 hours after birth and are often life-threatening. Vitamin К prophy­
laxis after birth cannot always prevent these intrapartum or early haemorrhages (33, 
34). Antenatal vitamin К supplementation via the mother has been suggested as an 
alternative. Before studying the effects of daily supplementation of 10 mg vitamin 
K; during the last month of pregnancy (chapter 8), an observational study was con­
ducted to establish the incidence of vitamin К deficiency in mothers and neonates 
exposed to AC (chapter 7). 
Incidence of vitamin К deficiency in neonates exposed to anticonvulsants 
In a multicenter case-control study, 25 mother-infant pairs on AC therapy and 25 
control pairs were studied for PIVKA-II and vitamin K; concentrations at 32 weeks 
of pregnancy and at delivery (chapter 7). Vitamin Kj plasma concentrations during 
normal pregnancy are reported to be normal (35) or slightly decreased (22). Vit­
amin Kj concentrations in pregnant women using AC were not reported before. 
They were found to be significantly lower than in control women, especially at 
delivery. This supports the previously mentioned hypothesis of an increased turnover 
of vitamin К due to induction of hepatic enzymes by AC (36, 37). Despite the de­
creased vitamin Ky concentrations, the women were not vitamin К deficient, since 
PIVKA-II was rarely detectable. Additional stores of vitamin K2 may be responsible 
for this. Neonates, on the contrary, lack hepatic vitamin K2 in the first 2 weeks of 
life (26). Because AC readily cross the placenta, they also induce fetal liver 
enzymes. Together with a placental barrier for vitamin Ky (paragraph 1.5.2), it is 
imaginable that fetuses exposed to AC are more likely to develop a vitamin К defi­
ciency. In accordance with the literature, vitamin Ky concentrations in cord blood of 
both groups were predominantly below the limit of detection (10,22,35). PIVKA-II 
was present in low concentrations in 20% of control cord samples, which is in 
agreement with other reports (10, 38). This again illustrates the marginal vitamin К 
status of normal infants at birth. In cord blood of neonates with antenatal exposure 
to AC, PIVKA-II was detected more frequently (54%) and in higher concentrations. 
Remarkably, valproic acid did not induce PIVKA-II in cord blood of exposed 
neonates, which is in accordance with the fact that valproic acid is not enzyme-
inducive (39). In conclusion, symptoms of vitamin К deficiency are more frequent 
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and more serious in neonates intra-uterinely exposed to enzyme-inducive AC than in 
controls. The mothers themselves have decreased vitamin Kj plasma concentrations, 
but usually are not deficient in vitamin K. 
Antenatal vitamin К prophylaxis 
In a consecutive multicenter study, 16 epileptic women using enzyme-inducive AC 
were treated with 10 mg vitamin Ky per day from the 36th week of gestation 
onwards (chapter 8). PIVKA-II was not detectable in any maternal or cord sample. 
The supplementation raised the median maternal vitamin K; level about 60-fold and 
the median cord level at least 15-fold. The median cord level was 530 pg/ml, which 
is approximately the normal adult level. A lower dose of vitamin Kj might be 
considered. Median maternal-cord ratio was 44, which is exactly the same ratio as 
reported by Mandelbrot et al. (40) in non-epileptic mother-infant pairs. There was 
no correlation between the cord vitamin K¡ concentrations and the duration of 
treatment, as confirmed by others (40, 41). In other words, supplementation during 
just a few days before delivery would be sufficient. To raise cord vitamin Kj 
concentrations, the vitamin must be administered at least 4 hours before delivery 
(18, 41). For correction of haemostasis more time might be necessary. Because the 
moment of delivery is unpredictable, it may be prudent to start at the 36th or 37th 
week of gestation. Some reports confirm that prenatal oral administration of vitamin 
К ; or K2 prevents hypoprothrombinaemia in the newborn (42,43,44), others how­
ever, do not (45). 
In conclusion, antenatal supplementation of vitamin Ky reverses the increased 
incidence of (biochemical) neonatal vitamin К deficiency caused by maternal 
enzyme-inducive AC therapy. This intervention may reduce the frequency of early 
haemorrhagic disease in newborns of epileptic mothers. 
9.5 SUGGESTIONS FOR FUTURE INVESTIGATIONS 
To prove efficacy of vitamin К prophylaxis, prospective randomized studies would be 
most appropriate. Such studies should involve a very large number of babies, since 
the incidence of HDN is low. For this, as well as for ethical reasons these studies 
are still lacking. 
Currently, research for vitamin К deficiency relies on the assessment of vitamin К 
status, which is based on either assessment of serum or tissue vitamin К concentra­
tions or on detection of non-carboxylated proteins. Until recently, most data 
available on tissue and plasma concentrations of vitamin К only regarded vitamin Kj 
and not vitamin K2. Now that determination of menaquinones is possible, much has 
to be learned about the impact of vitamin Kj in the development of vitamin К defi­
ciency and HDN. The alternative method to assess vitamin К status is based on the 
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detection of non or partially carboxylated proteins. In this thesis we used the 
detection of PIVKA-II and demonstrated that administration of extra vitamin К 
prevented the appearance of РГ КА-ІІ. It has been questioned, however, whether 
hepatic proteins, such as the coagulation factors, are the most sensitive markers for 
a vitamin К deficiency (46). Because it was shown in rats that at low concentrations 
of vitamin Щ, the liver preferentially absorbs the circulating vitamin K; (47), it is 
conceivable that extrahepatic tissues are depleted first. Consequently, the carboxyla­
tion of osteocalcin, a non-hepatic vitamin K-dependent protein (paragraph 1.6.2), 
might be affected in an earlier phase of vitamin К deficiency than prothrombin. In 
cord blood of healthy neonates the degree of carboxylation of osteocalcin was 
reported to be 30-40% of maternal carboxylation (48). It is unknown at present 
whether vitamin К supplementation increases the degree of carboxylation of osteo­
calcin. Whether osteocalcin may serve as an additional marker for studying vitamin 
К requirements, needs further confirmation. Therefore, a study has been initiated in 
co-operation with the research-group of Vermeer et al (Maastricht) to investigate 
simultaneously the carboxylation of osteocalcin and prothrombin in cord blood of 
healthy, term neonates. 
Another promising area of research is the development of mixed-micelles solutions 
of vitamin K ,^ which contain glycocholic acid and lecithine as solubilizers in stead of 
Cremofor EL. It was demonstrated that absorption of vitamin K7 from mixed-
micelles solutions is much better than from conventional solutions, especially in 
infants with cholestasis (49). The use of such a preparation might result in fewer 
failures of oral prophylaxis and fewer anaphylactoid reactions after intramuscular 
and intravenous administration, since preservatives are also omitted. Unfortunately, a 
suitable product for daily administration of low doses of mixed-micelles vitamin Щ 
is not yet available in the Netherlands. 
9.6 SUMMARY OF RECOMMENDATIONS 
Based on the results of this thesis, we recommend to adapt the recommendations of 
the Dutch Paediatric Association (32) as follows: 
- All healthy, term infants receive an oral dose of 1 mg vitamin K^  (1 drop of 
Konakion^ 20 mg/ml, Roche) within a few hours after birth. In other cases, for 
example perinatal asphyxia, complicated delivery or intra-uterine exposure to 
anticonvulsants, anticoagulants and rifampicine, an intramuscular injection of 1 mg 
vitamin Kj is preferred. When birth weight is less than 1500 grams 0.5 mg should 
be injected. 
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- Thereafter breast-fed infants are supplemented with an oral dose of 25 μg vitamin 
Kj daily (5 drops of Davitamon Κ , Chefaro) from 2 weeks until 3 months of age. 
Exclusively formula-fed infants do not need vitamin К supplementation after having 
recieved 1 mg at birth. 
- Pregnant women on enzyme-inducive anticonvulsant medication are prescribed an 
oral dose of 10 mg vitamin K; per day (1 tablet of Konakion^) from the 36th or 
37th week of gestation until delivery. 
We hope these recommendations will help to prevent all cases of HDN. In co­
operation with the Dutch Surveillance Center of Paediatrics (NSCK) a prospective 
survey was started to determine the incidence of HDN in the Netherlands and to 
examine the effect of current methods of vitamin К prophylaxis, using the system of 
monthly notification cards developed by the British Paediatric Surveillance Unit (50). 
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SAMENVATTING 
In hoofdstuk 1 worden de werking en pharmacokinetiek van vitamine K, de ver­
schijnselen bij vitamine К deficiëntie en de controversen met betrekking tot vitamine 
К profylaxe beschreven. 
Vitamine К is een co-factor voor het vitamine K-afhankelijke carboxylase enzym, dat 
betrokken is bij de produktie van de stollingsfactoren II, VII, IX en X en de 
stollings-inhibitoren proteïne С en S. Door de carboxylering van bepaalde glutamine-
zuur residuen tot Y-carbcoy-glutaminezuur residuen, zijn de eiwitten in staat met 
calcium te binden > Dit is nodig voor een goede haemostatische funktie. Indien de 
carboxylering gestoord wordt door een tekort aan vitamine K, verschijnen er onvol­
ledig gecarboxyleerde en daardoor a-functionele stollingsfactoren in het bloed. Deze 
worden "proteins induced by vitamin К absence" (PIVKA) genoemd. PIVKA-II (on­
volledig gecarboxyleerd prothrombine) werd in dit proefschrift gebruikt als sensitieve 
maat voor het bestaan van een vitamine К deficiëntie, naast de vitamine Kj plasma 
concentratie (hoofdstuk 2). 
Een vitamine К deficiëntie leidt tot een gegeneraliseerde bloedingsneiging. Op de 
zuigelingen-leeftijd worden 3 bloedingspatronen onderscheiden; vroege bloedingen 
binnen 24 uur na de geboorte, klassieke bloedingen op de 2e tot f dag, en late 
bloedingen na de eerste week (Tabel 1.5). De vroege en late bloedingen zijn vaak 
intracranieel geïdealiseerd, met frequent de dood of neurologische handicaps tot 
gevolg. Om deze bloedingen te voorkomen wordt op steeds grotere schaal vitamine 
К profylaxe toegepast. Desalnietemin bestaan er nog vele controversen omtrent de 
beste wijze, frequentie en dosis van toedienen, resulterend in een niet consistent be­
leid. Het doel van dit proefschrift was het vaststellen van adviezen ten aanzien van 
de preventie van vitamine К deficiëntie bij gezonde jonge zuigelingen. 
Omdat bij het foetale schaap chromosoom schade na intraveneuze injectie van vita-
mine K; is beschreven, werd allereerst een studie verricht naar de genotoxiciteit van 
vitamine К (hoofdstuk 3). Er werd geen toename gezien in zuster-chromatide uitwis­
selingen, noch in chromosoom breuken in perifere bloed lymfocyten 24 uur na de 
toediening van 1 mg vitamine Kj intramusculair aan de pasgeborene. Deze korte­
termijn mutageniciteits toetsen gaven aldus geen aanwijzingen voor een genotoxisch 
effect van de toediening van vitamine Kj aan de humane neonaat. Echter, lange-
termijn studies zijn gewenst. 
In de hoofdstukken 4, 5 en ti werden verschillende vormen van vitamine К profylaxe 
geëvalueerd op hun betrouwbaarheid in de preventie van late vitamine К defici­
ënties in gezonde, volledig borstgevoede zuigelingen. Het is onomstreden dat een 
éénmalige toediening van vitamine К beschermt tegen klassieke bloedingen. Late 
bloedingen kunnen echter optreden ondanks orale of intramusculaire vitamine К 
toediening post partum (Tabel 1.6). 
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In hoofdstuk 4 worden twee groepen van ongeveer 165 borstgevoede zuigelingen 
beschreven, die na de geboorte at random ofwel oraal ofwel intramusculair 1 mg 
vitamine Kj hadden ontvangen. Ondanks de significant hogere vitamine Kj plasma 
concentraties na intramusculaire toediening, was er geen verschil in Thrombotests, 
activiteiten van de stollingsfactoren VII en X, en PIVKA-II concentraties tussen de 
groepen. Op de leeftijd van 2 weken waren de vitamine K; concentraties in beide 
groepen hoger dan in ongesuppleerde kinderen en was er geen PIVKA-II aantoon­
baar. Dit geeft aan dat beide vormen van vitamine К profylaxe nog effectief zijn na 
2 weken. Op de leeftijd van 1 maand waren de vitamine K; concentraties over­
eenkomstig waarden in ongesuppleerde zuigelingen en was bij enkele kinderen 
РГ КА-ІІ detecteerbaar. Op de leeftijd van 3 maanden was in beide groepen in 
meer dan 10% van de zuigelingen PIVKA-II aanwezig, wat laat zien dat géén van 
beide éénmalige toedieningswijzen complete bescherming biedt tegen het optreden 
van late vitamine К deficiënties. 
In hoofdstuk 5 werden 48 borstgevoede zuigelingen bestudeerd die wekelijks 1 mg 
vitamine Ky per os kregen toegediend. Er traden geen tekenen van vitamine К 
deficiëntie op; alle zuigelingen hadden normale Thrombotest waarden en er was 
geen PIVKA-II aantoonbaar op de leeftijd van 1, 2 en 3 maanden. Op de leeftijd 
van 3 maanden was het vóórkomen van PIVKA-II significant minder dan na een 
éénmalige orale of intramusculaire toediening. De gemiddelde vitamine Kj con-
centraties vlak vóór de volgende gift, waren significant hoger dan na een éénmalige 
vitamine К profylaxe na de geboorte. Er trad geen accumulatie op. Het wekelijks 
toedienen van 1 mg vitamin Kj lijkt betrouwbaar in de preventie van late sympto­
men van vitamine К deficiëntie. 
In hoofdstuk 6 werden 58 zuigelingen met borstvoeding bestudeerd die na de toe-
diening van 1 mg vitamine Kj per os of intramusculair na de geboorte, vanaf de 
leeftijd van één week dagelijks 25 /ig vitamine К ; per os kregen toegediend. Even­
eens worden hier 10 zuigelingen beschreven die werden gevoed met een kunst­
voeding die tenminste 50 /ig/1 vitamine K^ bevat. Ook de toediening van 25 pg 
vitamine K; per dag voorkwam het ontstaan van PIVKA-II. Wederom varieerden de 
vitamine K; concentraties sterk interindividueel. Ze waren hoger dan na een één-
malige vitamine К profylaxe, maar lager dan in de flesgevoede zuigelingen. Er trad 
wederom geen accumulatie op. Of volstaan kan worden met nog kleinere hoeveel­
heden is vooralsnog onbekend. Of de voorkeur gegeven moet worden aan de dage­
lijkse of wekelijkse profylaxe toont dit onderzoek niet aan. Enkele overwegingen ten 
voordele van de dagelijkse toediening zijn: 
minder tijdsfluctuatie in plasma concentratie vitamine Kj 
de totale dosis die gegeven wordt in 3 maanden is beduidend minder (2.1 
versus 12 mg). 
dagelijkse toediening wordt eerder routine en daardoor minder gemakkelijk 
vergeten 
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indien een gift vergeten wordt of onopgemerkt uitgespuugd wordt, heeft dit 
minder langdurige consequenties. 
Hoofdstukken 7 en 8 hebben betrekking op de preventie van vroege bloedingen. 
Neonaten waarvan de moeder tijdens de zwangerschap anti-epileptica heeft gebruikt, 
hebben een risico voor bloedingen die reeds durante partum of binnen 24 uur op­
treden. Vitamine К toediening na de geboorte kan een ernstige afloop niet altijd 
meer voorkomen. Voordat het effect van prenatale vitamine К suppletie via de 
moeder werd bestudeerd, werd middels een observationele studie vastgesteld of de 
incidentie van vitamine К deficiëntie in deze groep neonaten inderdaad verhoogd is. 
In een multicentrum case-control studie werden 25 moeder-kind paren met anti-
epileptica en 25 controle paren bestudeerd voor wat betreft PIVKA-II en vitamine 
K, concentraties bij 32 weken amenorrhoe en na de bevalling (hoofdstuk 7). 
Ondanks de significant lagere vitamine K.¡ concentraties bij de vrouwen met anti-
epileptica, waren zij niet frequent vitamine К deficiënt daar zelden PIVKA-II aan-
toonbaar was. De beschikbaarheid van vitamine K2 reserves zou hieraan ten 
grondslag kunnen liggen. Neonaten daarentegen beschikken de eerste weken nog 
niet over vitamine K2 in hun lever en zijn geheel afhankelijk van vitamine Kj. De 
vitamine K; concentratie in het navelstrengbloed was in beide groepen meestal lager 
dan de detectielimiet, wat overeenkomt met de literatuur. PIVKA-II was aanwezig 
in 20% van de controle navelstreng-monsters, doch in lage concentraties. In het 
navelstrengbloed van de neonaten met intra-uteriene blootstelling aan anti-epileptica 
was PIVKA-II significant vaker (54%) en in hogere concentraties aanwezig. Val-
proinezuur gaf geen induktie van PIVKA-II. Dit komt overeen met de hypothese 
dat de verhoogde kans op vitamine К deficiëntie door anticonvulsiva, veroorzaakt 
wordt door enzym-induktie in de foetale lever. Valproinezuur is immers niet enzym-
inducerend. Geconcludeerd werd dat verschijnselen van vitamine К deficiëntie 
significant vaker en in ernstiger mate optreden bij pasgeborenen die intra-uterien 
blootgesteld worden aan enzym-inducerende anti-epileptica, dan bij controle kinder-
en. 
Vervolgens werden 16 vrouwen die enzym-inducerende anti-epileptica gebuikten, 
behandeld met 10 mg vitamine K^ per os per dag vanaf 36 weken amenorrhoe tot 
aan de partus (hoofdstuk 8). In geen enkel moederlijk of navelstreng monster was 
PIVKA-II aantoonbaar. De vitamine K^  concentraties in de navelstreng waren signi-
ficant gestegen. Geconcludeerd werd dat antenatale vitamine К suppletie de ver­
hoogde kans op neonatale vitamine К deficiëntie - veroorzaakt door matemaal 
enzym-inducerende anti-epileptica - te niet doet. Deze interventie kan mogelijk 
bijdragen in de preventie van vroege bloedingen bij pasgeborenen van moeders met 
anti-epileptica. 
In hoofdstuk 9 worden de resultaten besproken en samengevat. Eveneens worden 
suggesties voor verder onderzoek gegeven. 
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Het volgende beleid t.a.v. vitamine К profylaxe wordt voorgesteld: 
Alle gezonde voldragen pasgeborenen ontvangen 1 mg vitamine K^ per os 
(1 druppel Konakion'1 20 mg/ml, La Roche) binnen enkele uren na de ge­
boorte. In overige situaties, bv. bij kunstverlossing, asfyxie, aspiratie, ex­
positie aan anticonvulsiva, anticoagulantia of rifampicine, wordt 1 mg vita­
mine Kj intramusculair toegediend. Bij een geboortegewicht minder dan 
1500 gram wordt 0.5 mg gegeven. 
Zuigelingen met uitsluitend borstvoeding krijgen vervolgens vanaf de leeftijd 
van 2 weken tot en met 3 maanden, dagelijks 25 μg vitamine Kj per os toe­
gediend (5 druppels Davitamon К , Chefaro). Voor iedere flesvoeding die 
geïntroduceerd wordt vóór de leeftijd van 3 maanden, wordt dagelijks 5 /tg 
(1 druppel) minder gegeven. Zuigelingen gevoed met een gehumaniseerde 
flesvoeding behoeven geen vitamine К suppletie naast de toediening op de 
eerste levensdag. 
Aan zwangere vrouwen die enzym-inducerende anticonvulsiva gebruiken, 
wordt geadviseerd 10 mg vitamine K^ per dag in te nemen vanaf 36 of 37 
weken zwangerschap tot aan de partus. 
In samenwerking met het Nederlands Signalerings Centrum Kindergeneeskunde is 
inmiddels een studie gestart om de incidentie van bloedingen t.g.v. vitamine К defi­
ciëntie in Nederland vast te stellen en het effect van de voorgestelde vitamine К 
profylaxe te evalueren. 
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huis te Veldhoven (opleider: Dr. E.J.P. Lommen). 
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STELLINGEN 
behorend bij het proefschrift 
PREVENTION OF 
VITAMIN К DEFICIENCY 
IN INFANCY 
E.A.M. Comelissen 
1. Een éénmalige toediening van vitamine К aan borstgevoede zuigelingen is 
onvoldoende ter preventie van late vitamine К deficiënties (dit proefschrift). 
2. De dagelijkse toediening van 25 ^g vitamine K^ is adequaat ter preventie 
van vitamine К deficiëntie in gezonde jonge borstgevoede zuigelingen (dit 
proefschrift). 
3. De meeste flesvoedingen zijn (te) ruim gesuppleerd met vitamine Ky (dit 
proefschrift). 
4. Behalve een vitamine K/ tekort, hebben zuigelingen met borstvoeding ook 
een relatief tekort aan vitamine Kj vergeleken met kinderen met flesvoeding 
(voorlopige resultaten eigen onderzoek). 
5. Toediening van vitamine К aan een zwangere vrouw die enzyme-induceren-
de anti-epileptica gebruikt, voorkomt een vitamine К tekort bij het kind (dit 
proefschrift). 
6. Routine suppletie van vitamine К aan patiënten met cystic fibrosis is niet 
nodig (Cornelissen EAM, Lieburg AF van, Motohara K, Oostrom CG van. 
Acta Paediatr 1992;81:658-61). 
7. Kinderen met onbekend spierlijden lopen het gevaar eenzaam op te groeien 
(Ekeren GJ van, Cornelissen EAM, Stadhouders AM, Sengers RCA. Eur J 
Pediatr 1991;150:744-50). 
8. De Landelijke Neonatale Registratie en het Nederlands Signalerings 
Centrum Kindergeneeskunde kunnen een belangrijke basis vormen voor 
beleidsbepaling op het gebied van de kindergeneeskunde. 
9. Dat in vitro fertilisatie (IVF) frequent leidt tot drie- en meerlingen is een 
uiting van onvolwassen technologie met mogelijk kwalijke gevolgen voor 
ouders en kinderen. 
10. Het middels echografie vaststellen van een toegenomen wanddikte van de 
blaas van een pasgeborene is een belangrijke indikatie voor de diagnose 
urethrakleppen. 
11. Degenen die moedermelk aanraden omdat het het intellect zou bevorderen 
(Lucas et al. Lancet 1992;339:8788), dienen zich te realiseren dat slimmer 
niet gelijk is aan gelukkiger. 
12. Het probleem van de mestoverschotten kan niet alleen op de boeren 
worden afgewenteld, maar is een verantwoordelijkheid van de hele 
maatschappij. 
13. Het bewerken van een proefschrift tijdens de opleiding kindergeneeskunde 
is in lichte mate ongunstig voor de opleiding en uitzonderingen daargelaten 
in grote mate ongunstig voor het onderzoek. 
14. Het feit dat babykamers meestal in pastelkleuren blijven ondanks het ver-
anderen van de mode, getuigt van conservatisme in deze periode. 
Marlies Cornelissen 
Nijmegen, 8 december 1992 
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